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Therapeutic benefits of medicinal cannabis are well documented in the treatment of a 
variety of medical conditions. There is not, however, a nationally consistent delivery 
system, which has prevented many patients from realizing these benefits. Using policy 
feedback theory as the foundation, the purpose of this general qualitative study was to 
better understand how state-level regulatory efforts in medicinal cannabis may provide 
guidance on formulating national public policies that are beneficial to patients. This study 
compared 3 core tenets of NORML, an authority in the cannabis industry, against the 
policies of 3 states with exemplary state medical cannabis programs. The tenets included 
access to whole-plant cannabis, wide latitude for doctors to decide treatment regimens, 
and the right to cultivation for personal use. Data collected from publicly available 
documents such as legislative archives, state government websites, cannabis coalition 
groups, and media coverage of medicinal cannabis legislation were deductively coded 
and subjected to a cross-case analysis procedure. Findings indicated a lack of full 
alignment with NORML’s core tenets as well as significant gaps between research on the 
efficacy of medical cannabis and the regulatory systems governing delivery within the 
states. Future policy makers may consider these results in devising nationwide legislation 
to research and recognize the medicinal use of cannabis, thus addressing the identified 
need for a uniform delivery system in the US for patients in need of cannabis for medical 
purposes. This study may contribute to positive social change through recommendations 
to federal legislators for creating a national government model for patient access to 
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Chapter 1: Introduction to the Study 
Introduction 
The purpose of this research study was to address the need for an increased 
understanding about the possibilities of developing a delivery system for medicinal 
cannabis for the treatment of diseases in the United States. Medicinal cannabis, consisting 
of dried leaves and flower buds from a natural plant, has therapeutic use for treating 
chronic and debilitating ailments. According to Seamon et al. (2007), “Marijuana 
contains more than 460 active chemicals and over 60 unique cannabinoids. The major 
active ingredient in marijuana is tetrahydrocannabinol (THC), which is primarily 
responsible for its therapeutic and psychoactive effects” (p.1038). Medical cannabis 
merits consideration as a relevant option in the United States for those patients suffering 
with specific diseases. This study is critical to understanding the possibilities of a formal 
delivery system for patient access that is considered an acceptable practice as determined 
by patient and physician and not restricted by federal law. Therefore, the potential social 
implication of this study is that information may help patients requiring medical cannabis 
for disease treatment find ways to access, purchase, possess, and use cannabis to treat 
their disease without the fear of potential criminal prosecution under federal law. 
Background 
The use of medicinal cannabis and the possibilities of a delivery system in the 
United States can provide benefits for patients suffering from certain diseases. According 
to Reinarman et al. (2011), marijuana is useful in treating seizures, muscle spasms, 
headaches, anxiety, nausea, vomiting, depression, and diarrhea. Moreover, it has also 
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proven to improve appetite, sleep, and concentration. In addressing medical cannabis’s 
therapeutic effectiveness, Lucas (2012) claimed its use lessened chronic pain and allowed 
patients an opportunity to reduce their use of pharmaceutical opiates. Additionally, 
Moeller et al. (2015) noted the increase in the number of health care professions who 
recognize the benefits and use of medical cannabis, also finding that pharmacy students 
support cannabis legalization for medicinal use. Moreover, Bonn-Miller, Boden, 
Buscossi, and Babson (2014) provided information on oncology palliative care patients 
who used medical cannabis and experienced a reduction of nausea, vomiting, and pain as 
well as decreased suffering from diminished spasticity and intraocular pressure. 
A public political debate over medicinal cannabis as a treatment of disease in the 
United States has resulted in proposals to Congress for new regulations. For example, 
introduction of the Legitimate Use of Medicinal Marijuana Act of 2014 was to allow state 
officials to legally move toward an appropriate use of medical marijuana without fear of 
federal criminal prosecution. Also proposed was the Respect States and Citizens’ Act of 
2017 introduced in the House of Representatives. If enacted, this bill would have 
amended federal law by decriminalizing the possession, distribution, and cultivation of 
state-regulated medical marijuana. In this case, the Federal Food, Drug, and Cosmetic 
Act of 1938, 21 U.S.C. § 301 et seq. would no longer supersede state law, thus allowing 
for the therapeutic use of medical marijuana.  
However, the results of Gonzales v. Raich (2005) influenced future public policies 
and laws regarding the emerging issue of medical cannabis and federal regulation. This 
case has precedence, so currently proposed policies would need to override the court’s 
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decision and change federal authority. The authority vested in Congress by Article I, §8, 
of the United States Constitution (Constitution) sets the precedence as “to make all Laws 
which shall be necessary and proper for carrying into execution its authority to regulate 
Commerce with foreign Nations, and among the several States includes the power to 
prohibit the local cultivation and use of marijuana in compliance with California law” 
(Gonzales v. Raich, 2005), thus establishing case law precedence for medicinal cannabis. 
The majority opinions held that the Controlled Substances Act of 1970 (CSA) prohibits 
the possession and/or manufacture of medical cannabis. Authority falls under the 
Commerce Clause regarding this issue, and California statute does not exceed the 
authority of Congress.  
This study allowed me to address the gap in knowledge regarding the lack of and 
possibilities for a delivery system development allowing U.S. patients to use medicinal 
cannabis for the treatment of diseases. The information from this study is critical and may 
be helpful in the creation of a formal delivery system of medicinal cannabis as a best 
practice across state lines, since federal law currently does not recognize the medicinal 
properties of cannabis. 
Problem Statement 
Researchers have well documented the therapeutic and medicinal benefits of 
cannabis (Hill, 2015; Webb & Webb, 2014). Cannabis is useful in treating seizures, 
muscle spasms, headaches, anxiety, nausea, vomiting, depression, diarrhea, and multiple 
types of pain (Lucas, 2012; Reinarman et al., 2011). Researchers also support that many 
patients do not respond to existing pharmacological treatments and could benefit greatly 
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from the use of medicinal cannabis (Koppel et al., 2014). Currently, the federal 
Controlled Substances Act, Title II, of the Comprehensive Drug Abuse Prevention and 
Control Act of 1970, which prohibits local cultivation and use of marijuana, governs 
medical cannabis.  
The general problem is the United States does not have a formal delivery system 
for accessing medicinal cannabis, as federal law does not recognize its medicinal 
properties. With changes in state policies since the 1970s and growing research on the 
medicinal value of cannabis, it is necessary to revisit the possibilities for a delivery 
system of cannabis for the treatment of diseases in the United States. More than 30 states 
are exploring this emerging issue by establishing or implementing laws legalizing the 
delivery and use of medical marijuana for qualified patients. 
Purpose of the Study 
The purpose of this research study was to address the need for an increased 
understanding concerning the lack of and possibilities for the development of a medicinal 
cannabis delivery system for use in the treatment of diseases in the United States. As the 
United States does not currently have a formal delivery system for medicinal cannabis, 
research at the state level would facilitate exploration of initiatives and system 
possibilities. For example, patients whose physicians provide written recommendations 
could legally obtain medicinal cannabis as treatment for disease. Therefore, patients 
could possess, transport, and conduct activities related to medical cannabis within the 
confines of their state’s medical cannabis laws. The patient’s quality of life will improve 
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by mitigating chronic illnesses and/or diseases by using cannabis as a viable treatment 
option without fear of arrest or federal criminal prosecution.  
Virginia Republican Morgan Griffin introduced H.R. 4498 on April 28, 2014, 
legislation known as the Legitimate Use of Medicinal Marijuana Act, in an attempt to 
reclassify cannabis under the federal CSA from a Schedule 1 to a Schedule 2 drug. This 
would have eliminated existing restrictions on medical cannabis research and provided 
greater freedom to authorize cannabis treatment by physicians. In addition, the Act would 
have prohibited the federal government from interfering with a patient’s access to 
medicinal cannabis in states where it was legal. If the bill had passed, it would have 
amended federal law by decriminalizing the possession, distribution, and cultivation of 
state-regulated medical cannabis. As a result, the FFDCA (1938) would no longer 
supersede state law, allowing for the therapeutic use of medicinal cannabis.  
Introduced in the House of Representatives on February 14, 2013, was another 
legislative bill known as the States Medical Marijuana Patient Protection Act. According 
to this Act: 
[N]o provision of the Federal Food, Drug, and Cosmetic Act shall prohibit or 
otherwise restrict an entity authorized by a state or local government, in a state in 
which the possession and use of marijuana for medical purposes is legal from 
producing, processing, or distributing marijuana for such purpose. (States Medical 
Marijuana Patient Protection Act, 2013) 
To this effect, I employed a qualitative cross-case analysis to fill this identified 
gap in research and legislation surrounding the delivery of medicinal cannabis. Through 
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the inclusion of National Organization for the Reform of Marijuana Laws’ (NORML; 
2019) three core tenets, the goal in this research study was to compare perspectives of 
other state practices. The core tenets of NORML’s patient-centric, evidence-based 
medical cannabis program include (a) patient access to the whole plant, (b) a list of 
qualifying medical conditions, (c) and patients’ legal options to cultivate for personal use 
in their private residence (NORML, 2019). I used policy feedback theory as a base and 
triangulated policy practices. While the literature includes related issues like the 
legalization of cannabis at the federal level or the rescheduling of cannabis under the 
CSA, researchers have not included the lack of and possibilities for a delivery system 
development for U.S. patients to use medicinal cannabis. This study was necessary 
because states have already implemented different types of medical cannabis programs, 
policies, rules, and regulations; thus, it addressed this research gap. 
Research Question 
RQ: How do state-level regulatory efforts in medicinal cannabis provide guidance 
on formulating national public policies that are most beneficial to patients in the United 
States? 
Theoretical Framework for the Study 
The theoretical lens for framing this research study was Mettler and SoRelle’s 
(2014) policy feedback theory. According to Mettler and SoRelle and Sabatier and 
Weible (2014), this framework is applicable for addressing the formation of policy and 
for conducting an examination of the dynamics of and societal response to policies. For 
example, the court’s decision in Gonzales v. Raich (2005) influences current and future 
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laws regarding the emerging policy issue of medicinal cannabis and federal regulation. 
Although this case established precedence, legislators are currently putting forth policies 
intended to override the court’s decision and eventually change federal law. Researchers 
support these changes with cases of patients with numerous medical issues who used 
state-approved medicinal cannabis with positive results and no serious side effects (Webb 
& Webb, 2014). Finally, it appears that public opinion has shifted over the last several 
decades toward a greater social acceptance of state laws regulating medical cannabis 
(Koppel et al., 2014). 
Nature of the Study 
In this study, I used a qualitative method to compare and contrast regulatory cases 
across states. Qualitative research was most appropriate to understand the lack of and 
possibilities for a delivery system in the United States for the use of medicinal cannabis 
in the treatment of diseases. With a qualitative approach, the researcher assesses 
information and knowledge gained from a particular audience through case studies. Data 
collection for this study occurred through a review of legislative records, memos, state 
government websites, cannabis coalitions, and documents available on medicinal 
cannabis programs. I conducted a cross-case analysis comparing three exemplary state-
implemented medical cannabis programs for common and dissimilar elements and 
subsequently compared these programs to three of NORML’s patient-centric, evidence-
based medical cannabis program core tenets: (a) patient access to the whole plant, (b) an 
expansive list of qualifying medical conditions, and (c) the patients’ legal option to 
cultivate plants for personal use in their private residence (NORML, 2019). I engaged in 
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Internet-based and hard copy data collection to compare patterns and ideas regarding 
current and future regulatory efforts and policies for medicinal cannabis in the United 
States and to show how existing policies impact equal access. With this type of research 
design, I allowed for a detailed description of the phenomena by each of the study 
entities, including mitigation of personal bias, identification of particular experiences, 
creation of units of themes and patterns for statements, and individual case descriptions. 
Definitions 
Policy: Course of action at all levels of government (and individuals) adopted or 
proposed through a government body (Sabatier & Weible, 2014). 
Marijuana: A green/brown mix of dried flowers, stems, leaves, and seeds from 
the flowering tops of the hemp plant, Cannabis sativa (National Institute on Drug Abuse, 
2017). These tops contain cannabidiol, cannabinol, and isomeric tetrahydrocannabinols 
(Marijuana, 2017). 
Medical or medicinal cannabis: Cannabis products (plant or extracts) ingested for 
the treatment of symptoms caused by an illness (National Institute on Drug Abuse, 2017). 
Using medicinal cannabis/marijuana for the treatment of diseases: Consumption 
for medicinal and/or therapeutic reasons. The California State Legislature Medical 
Marijuana Research Act of 1999 allowed the Center for Medicinal Cannabis Research to 
conduct clinical trials of smoked cannabis in the United States. As a result of this 
systematic research, researchers supported the idea of utilizing cannabis as treatment in 
selected pain syndromes and muscle spasticity caused by injury or diseases of the 




The regulatory transformation in using medicinal cannabis to treat diseases in the 
United States may have suffered from the lack of a formal delivery system to patients 
because federal law does not recognize cannabis as medicinal. For this study, I assumed 
past federal regulations were successful in preventing equal access to medicinal cannabis 
used by patients to treat diseases within the United States. The success of past methods 
used by federal regulations for different issues can guide the transformation of 
regulations on medical cannabis to help establish a formal delivery system for future 
success in treating diseases in the United States.  
Another assumption was that regulatory transformation and a formal delivery 
system are the best methods for changing regulations for the treatment of diseases in the 
United States. Given the lack of central direction from the federal government, other 
bills, memoranda, and state laws served as policy laboratories to promote medicinal 
cannabis use and regulate some form of delivery system. In this study, I used a cross-case 
analysis to measure three exemplary state-implemented medical cannabis programs 
against a benchmark of three of NORML’s patient-centric, evidence-based medical 
cannabis program core tenets. I assumed NORML would be the best source of 
information for determining regulations and a formal delivery system that provides equal 
access to all patients needing medical cannabis. 
Scope and Delimitations 
The current regulations for medicinal cannabis delivery systems have impacted 
the regulatory transformation in using this product to treat diseases. This cross-case 
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analysis facilitated comparison of three states that have implemented exemplary medical 
cannabis programs against three of NORML’s medical cannabis program core tenets. 
NORML was the benchmark as a leading authority in medical cannabis regulations. I 
identified the three states that have implemented exemplary medicinal cannabis programs 
as an ideal sample population because each has established compelling, yet unique 
programs and served as a model for others states’ regulatory efforts. Currently, regulatory 
inconsistencies exist among the states that have implemented medical cannabis programs, 
and the result has been a plethora of different medical cannabis policies.  
Limitations 
In a qualitative research inquiry, rules regarding sample size are fluid (Patton, 
2015). The sample size necessary to generate meaningful qualitative data via in-depth 
inquiry for this study was relatively small. Consequently, the data collected could be too 
limited for the purpose of generalization. However, according to Patton (2015), the logic 
and power of purposeful sampling lie in selecting information-rich cases for an in-depth 
study. First, this sample population represented those states leading the medical cannabis 
regulatory efforts. Furthermore, all states lacked a model to follow, and therefore they 
have become inconsistent in their regulatory policies. States that implemented policies 
after the three states in this sample partially followed the patterns and practices of those 
three exemplary programs, but they also implemented unique regulations largely driven 
by politics. The inconsistency has created a range of different medical cannabis policies 




In this research study, I identified how perceptions of regulatory efforts regarding 
medicinal cannabis shape policies in the United States and the gaps in the regulatory 
systems that govern delivery. I also reviewed existing research supporting the value of 
medicinal cannabis. Through these efforts, this study may lead to positive social change 
by potentially improving the lives of ill individuals who could benefit from treatment 
with medicinal cannabis. Although clear policies governing medicinal cannabis exist at 
the federal and state levels, practical implications from this research include policy 
recommendations for incorporation of evidence-based research about the use of medical 
cannabis for the treatment of disease. Furthermore, the significance of this study is that it 
may provide additional data to aid in improving systems of government oversight for 
current and future programs and policies. In terms of implications for social change, this 
study’s findings could result in better and more consistent future public policy regarding 
the establishment of a systematic delivery system of medicinal cannabis for the treatment 
of specific diseases. 
Summary 
In this study, I sought to use a qualitative cross-case analysis to explore regulatory 
transformation for the use of medicinal cannabis to treat diseases in the United States. 
The use of medicinal cannabis is growing. Individual state regulatory changes over the 
last several decades have increased as a result of well-documented therapeutic research 
on the medicinal benefits of cannabis treatment for diseases. However, the CSA, which 
prohibits local cultivation and use of marijuana, regulates medical cannabis in the United 
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States. The United States does not have a formal delivery system for accessing medical 
cannabis. Exploring the lack of and possibilities for a delivery system for medical 
cannabis usage was essential. The results of this study may spur regulatory 
transformation that will help qualified patients throughout the United States legally 
access, possess, and cultivate medicinal cannabis to treat their diseases without the fear of 
federal criminal prosecution. Chapter 2 provides an overview of researchers who have 
explored United States policy and evidence-based research regarding medicinal cannabis 
use, including current and potential future government oversight policies. 
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Chapter 2: Literature Review 
Introduction to Literature Review 
This chapter includes an exhaustive review of existing literature that addresses the 
need for an increased understanding about the lack of and possibilities for the 
development of a formal delivery system for accessing medicinal cannabis for the 
treatment of disease in the United States. The goal was to gain insight into policy 
recommendations that incorporate evidence-based research on the use of medicinal 
cannabis for the treatment of disease, along with improving systems of government 
oversight for current and future policy. This chapter includes the theoretical framework 
and history of medicinal cannabis, contemporary uses of medicinal cannabis for 
therapeutic benefits, the statutory basis for delivery systems currently established by the 
United States government, and the delivery systems currently established by foreign 
governments for medicinal cannabis. The theory most appropriate for the framing of this 
proposed research was the policy feedback theory that, according to Mettler and SoRelle 
(2014), provides a look at the formation of policy and an examination of the dynamics 
and societal response to policies. I conducted a thorough analysis of existing literature 
supporting the history of medicinal cannabis, the contemporary uses and therapeutic 
benefits of medicinal cannabis, and gaps between the regulatory system governing the 
delivery of medicinal cannabis and research supporting the value of medicinal cannabis 
for the treatment of disease in the United States.  
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Literature Search Strategy 
The review of literature for this research study involved myriad search terms and 
resources related to policy, policy feedback theory, marijuana, cannabis, medical or 
medicinal cannabis, and medicinal cannabis for the treatment of disease. I used these 
keywords and key terms as a guide to peer-reviewed journals, books, articles, and 
documents from the following sources: Walden University library, the NORML website, 
and state and federal laws, regulations, and policies. The search engines used for this 
literature review included ProQuest, EBSCOhost, ProQuest Dissertations & Theses 
Global, and Sage. The extensive number of research inquiries yielded an exhaustive 
overview of the current body of literature concerning the problem and purpose of this 
study.  
Policy Feedback Theory 
The social paradigm of policy design pertains to groups either positively or 
negatively through the interpretation of policy creation. The multifaceted theory of policy 
subsystems leaves people to depend upon heuristic processes and thinking. Analytic 
familiarity and knowledge becomes paramount because much of public policy involves 
fundamental processes (Weible et al., 2011). Theories concerning public policy can serve 
as frameworks to improve understanding of the policy process. Furthermore, the policy 
sciences are cornerstone to the framework most applicable to this research study. 
Empirical researchers can support policy design and collective achievements to facilitate 
problem-solving that influences policy processes in the overarching policy feedback 
theory (Weible et al., 2011).  
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The systematic approach to allocate benefits to the policy recipients (target 
groups) appears in social groups versus individual acuities (Maltby, 2017). Developed by 
Mettle and SoRelle (2014), policy feedback theory served as an appropriate theoretical 
foundation for this study because of the interpretative effects of the problem and purpose 
statements. The existing policy for medicinal cannabis delivery systems leaves patients 
unable to travel across state lines with cannabis in their possession (Interstate Commerce 
Act of 1887, 49 U.S.C. § 3-22). The complexity of medicinal cannabis regulatory efforts 
and existing policies that impact patients in the United States aligns with policy feedback 
theory. Social groups endure the impact of existing laws and policies. In this regard, an 
enhanced understanding of the lack of and possibilities for the development of a delivery 
system is needed. The United States does not currently have a formal delivery system for 
medical marijuana.  
Theoretical Overview 
Upon policy enactment, implementation aids in developing structure while 
providing benefits to groups of people. Policy feedback theory encompasses the 
importance of policy design and its impact on political agendas and groups of people 
(Mettler & SoRelle, 2014; Sabatier & Weible, 2014). The cornerstone of policy feedback 
theory are historical aspects, which reveal that past pledges create cumulative returns that 
lead to enduring efforts (Cairney, 2012; Pierson, 2002). The policy feedback theory is 
broad in focus, thus applicable to the cross-case analysis between the states chosen for 
this study in comparison to NORML’s three tenets.  
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The concept of policy feedback theory encompasses policy feedback and its 
various effects. As policy feedback theory is an implicit defined theory, a causal 
postulation exists supporting the validation for the effects of any given policy. As 
Sabatier and Weible (2014) asserted, the meaning of citizenship affects future policies 
and results from the power of groups, political agendas, and systems of governance. In 
line with policy feedback theory, an individual’s preferences and decisions are largely 
molded by policies. While a variety of policy theories exist, the policy feedback theory 
draws upon three distinct components: the independence of the three NORML tenets, the 
connection between these three concepts, and the correspondence resulting in policy 
evolution. This theory is largely tautological and relies heavily on knowledge acquisition 
(Sabatier & Weible, 2014). Furthermore, the levels of analysis and scope are implicit, 
describing how policies form policymaking and subsequent politics (Sabatier & Weible, 
2014). With more than 30 states having established laws legalizing the use and 
possession of medicinal cannabis for the treatment of disease, a need exists for an 
improved delivery system. The policy feedback theory is appropriate for an overview of 
the established policies on medicinal cannabis for the treatment of disease and the need 
for a sound delivery system (Mettler & SoRelle, 2014). 
Other Theories 
Given that personal experiences are pertinent in forming political beliefs and 
attitudes (Mettler & Soss, 2004), “the term ‘policy feedback’ describes the process 
through which public policies shape political outcomes, which in turn either reinforce or 
undermine the policy itself” (Lerman & McCabe, 2017, p. 626). Policy feedback theory 
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provided the strongest theoretical foundation for the comparison and analysis of the 
development of delivery systems for U.S. patients in need of medical cannabis for the 
treatment of disease. As such, other theories are not applicable and fall short, since policy 
feedback theory is best suited for this cross-case analysis.  
Just as new policies impact the creation of changing politics, they also shape 
social group incentives, capacities, and resources. The institutional analysis and 
development theory serves as a framework that stems from the action of people and their 
associated goals to develop policies (Lerman & McCabe, 2017). The institutional 
analysis and development theory was not ideal for this cross-case analysis because of its 
focus on a single action or situation that provokes adaptive decisions and constant 
adjustments over time. The advocacy coalition framework was also not appropriate for 
this study because of its focus on process emergence as a result of competition or conflict 
over time (Sabatier & Jenkins-Smith, 1993); in turn, this process involves long periods of 
political conflict or attempts to mediate agreements. In addition, the punctuated 
equilibrium theory did not fit this research study because of its view of policy from an 
empirical view. According to the punctuated equilibrium theory, like people, the political 
system is unable to consider all issues simultaneously, and therefore, introductions of 
subsystems are a means to exercise parallel processing. The reason this theory is not 
applicable is because it is inherently conservative yet predisposed of sporadic radical 
change (Sabatier & Weible, 2014); therefore, the punctuated equilibrium theory becomes 
irrelevant amid the periodic changes that occur within the political system.  
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Policy feedback functions most strongly among individuals and/or groups whose 
understanding of politics writ large may still be somewhat limited. Another benefit policy 
feedback theory offered this study was that research in support of the delivery of specific 
policy information may also stimulate opinion formation in individuals with lower levels 
of civic or policy knowledge (Lerman & McCabe, 2017). Using the policy feedback 
theory as a foundation for this cross-case analysis, I sought to explore how regulatory 
efforts concerning medicinal cannabis create policies that benefit U.S. patients.  
The reason for selecting this theory over others was the need to consider 
heuristics to assist in reasoning due to the complexity and purpose of the study. 
Heuristics allows for efficiently allocating attention, thereby simplifying incoming 
stimuli for better interpretation and understanding (Weible et al., 2011). However, the 
boundaries set with policy provide some degree of structure, albeit a broad focus in the 
nature of this study: the development of an improved delivery system for medical 
cannabis for U.S. patients. With more than 30 states having established laws to legalize 
medicinal cannabis, the structure provided by the policy feedback theory facilitated 
support of individuals and groups who may not be privy to the intricate details of policy. 
Furthermore, because the United States does not have a formal delivery system for 
medicinal cannabis, patients are limited in access of necessary medicine. 
Policy Feedback Theory Evolution 
Whether internal of external, changing conditions impact the dynamics of a 
policy’s subsystem (Sabatier & Weible, 2014). As such, policy change is the result of 
conditions that warrant evolution. Alterations to socioeconomic conditions shift advocacy 
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alliances and make changes in policy possible. The process of policy feedback theory is 
change and effect, with public policy fundamentally dependent upon implementation. 
The feedback element functions as a result of changes within the policy components that 
then lead to policy design changes, subsequently creating or strengthening existing social 
structures and groups. Through the policy feedback theory, the demand arises for 
subsystem contributions. Policy feedback theory stems from the adage that “policy 
creates politics” (Mettler, 2002; Mettler & SoRelle, 2014: Nowlin, 2016).  
As Soss and Schram (2007, as cited by Maltby, 2017) posited, the chief strength 
of policy feedback theory is the ability to impact people’s lives in concrete and direct 
ways. The two dominant approaches concerning policy theories come from policy 
analysis scholars and policy process scholars. The benefit of the policy feedback theory is 
that it rests between these two positions (Mettler & SoRelle, 2014). Another key concept 
is that policy should be more apparent in groups of individuals who find their lives 
targeted by the issue. Furthermore, analytic knowledge is only one aspect, albeit a 
limiting one to some extent, as bias may creep in when simplifying a phenomenon 
(Weible et al., 2011). Therefore, the empirical-based approach to the policy feedback 
theory supports the need for the development of an improved delivery method for 
medicinal cannabis for U.S. patients.  
As past policy interactions, federal and state laws and policies also contradict one 
another. Federal law and state law have established precedence, yet such precedence has 
prevented development of such a system. The irregular policy action, policy precedence, 
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and political environment are in conflict, and with federal law superseding state law, 
there is no uniform cannabis delivery system. 
History of Medicinal Cannabis 
The theoretical framework and history of medicinal cannabis provide a foundation 
for this study, demonstrating how political factors, propaganda, and regulatory efforts 
have impacted medicinal cannabis over time. Further, theoretical underpinnings support 
the progression of public policy regarding the use of cannabis for medicinal purposes. 
The use of medicinal cannabis from the 1930s to date has notably advanced in status and 
regulation.  
Prior to the 1930s, physicians used medicinal cannabis as a common course of 
treatment for chronic pain (Hall, 2015; McKenna, 2014). For instance, in 1887, doctors 
introduced medicinal cannabis as a daily treatment plan for individuals suffering with 
chronic migraine and/or headache pain (Baron, 2015; Greenwell, 2012; Hill, 2015). In 
1890, the president of the British Medical Association advocated for cannabis and its 
medicinal value for the treatment of numerous illnesses, specifically migraine and 
neuralgia, over a 30-year period (Baron, 2015; Hill, 2015; Warf, 2014). In 1915, Sir 
William Osler, considered the father of modern medicine, argued that cannabis was likely 
the most satisfactory remedy for the treatment of migraines (Baron, 2015).  
Furthermore, in 1916, Dr. Dixon, a professor of pharmacology at several 
prestigious universities, noted therapeutic benefits of medicinal cannabis in the treatment 
of migraine headaches (Baron, 2015; Carter, 2013; Kuddus, Ginawi, & Al-Hazimi, 
2013). According to Baron, American pharmacopeias included cannabis for the 
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prevention and treatment of headaches during this time. Additionally, numerous other 
well-known physicians advocated for medicinal cannabis as treatment throughout the 
19th and 20th centuries (Baron, 2015; Horowitz, 2014). For example, the president of the 
New York Neurological Society Dr. William Osler advocated extensively for the 
medicinal use of cannabis for the treatment of headaches. The following is review of 
changes that occurred with regard to medicinal cannabis during the 1930s. 
In the 1930s, amid favorable political factors, prominent members of the business 
community were able to mitigate and eventually eliminate the use of medicinal cannabis 
as a therapeutic treatment of illness and disease (Horowitz, 2014; Kuddus et al., 2013). 
They did so through the use of propaganda portraying cannabis as a drug abused by low-
income and minorities (MacDonald & Pappas, 2016). According to Baron (2015) and 
Routh (2017), efforts included a campaign overseen by Harry Anslinger and the Federal 
Bureau of Narcotics, a scare tactic associating medicinal cannabis use with psychosis, 
deterioration of mental capacity, and violent crimes. What resulted was the creation of 
the Marihuana Tax Act of 1937, enacted despite opposition by the American Medical 
Association (Routh, 2017).  
According to Baron (2015), a substantial tax on both the medical cannabis and 
hemp industries reduced its growth, given the potential for hefty fines and criminal 
prosecution for noncompliance; political powers and protests from the medical 
community were not enough to prevent the prohibition of medicinal cannabis. In 1941 
came the removal of medicinal cannabis from the United States Pharmacopoeia and 
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National Formulary. Moreover, legislative changes by the federal government in the 
1970s did not help medicinal cannabis. 
The phenomenon is a lack of consistency in public policy and state and federal 
regulations concerning the use of medicinal cannabis for patients. Policy analysis is a 
response to practical issues with an understanding of historical cognizance. However, the 
role that technical information plays in the policy process is only part of the equation 
(Lerman & McCabe, 2017; Sabatier & Weible, 2014). As Lerman and McCabe asserted, 
intellectual action rooted in a social process merits address by policy analysis. Policy 
feedback theory derives from the reality that political learning is largely tied to 
partisanship and opinion formation drawn from political messaging and secondary 
sources. As such, public policies are learned via personal experiences, thereby forming 
policy feedback (Lerman & McCabe, 2017; Sabatier & Weible, 2014). Policy feedback 
theory is appropriate for this study due to the need for improved understanding 
concerning the current deficiency and opportunities for the development of a delivery 
system for the use of medicinal cannabis for the treatment of disease in the United States. 
Changes in Medicinal Cannabis During the 1970s 
The federal government maintained the removal of medicinal cannabis from the 
United State Pharmacopoeia and National Formulary in 1941. In 1970, the federal 
government classified cannabis as a Schedule 1 narcotic under the CSA (Kamin, 2012; 
Routh, 2017). As a result, the U.S. federal government prohibits the distribution, 
possession, cultivation, and sale of cannabis. Additionally, physicians cannot prescribe 
cannabis to their patients due to licensing requirements by the U.S. Food and Drug 
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Administration (FDA; Kamin, 2012; Routh, 2017). The federal government’s 
classification of cannabis under the CSA defines it a drug with no acceptable medicinal 
value and a high possibility of addiction. Therefore, “the federal courts have held that a 
state’s adoption of medical marijuana provisions is irrelevant in a federal prosecution 
under the CSA” (Kamin, 2012, p. 979). 
Moreover, groups of individuals within the United States known as “hippies,” a 
culture of recreational cannabis users, increased prior to the regulatory implementation of 
the 1970 CSA (Hall, 2015). According to McKenna (2014), “hippies” were mainly part 
of the antiwar movement and included protesters, students, and members of college 
faculty. The enactment followed the hippie movement, when recreational use became 
intertwined with the medicinal use of cannabis. As a result, it was very difficult for 
experts to conduct research and/or give opinions on the effectiveness of medicinal 
cannabis as a therapeutic treatment for disease (Hall, 2015). Currently, however, the 
treatment of disease with medicinal cannabis has become a major component of 
individual state laws legalizing its use. 
Current Status of Medicinal Cannabis in the United States 
This phenomenon of medicinal cannabis in the US appears often in existing 
literature and research; therefore, addressing the current status of medicinal cannabis in 
the United States may also benefit from this review. Currently, more than 30 states are 
establishing or have implemented state laws legalizing the use of medicinal cannabis for 
qualified patients (Maxwell & Mendelson, 2016), with studies underway in several more 
states. Qualified patients are able to possess and cultivate medicinal cannabis without fear 
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of criminal federal prosecution as long as they remain compliant with state laws, rules, 
and regulations. Individual states have developed a medicinal cannabis program that 
allows patients to use and access medicinal cannabis through state- and locally regulated 
dispensaries (Freisthler & Gruenewald, 2014). Moreover, according to Maxwell and 
Mendelson (2016), medicinal cannabis regulation differs state by state regarding the 
criteria of who can recommend and/or prescribe medicinal cannabis and who can become 
a qualified patient of the program. However, as is apparent by the current politics, public 
policy, and case law within the United States, there are many regulatory gray areas 
(Lucas, 2012; Rosenberg, 2015). 
For instance, representatives have introduced several legislative bills related to 
legalizing medical cannabis. Given this political shift, currently there are two legislative 
bills (H.R. 714 and H.R. 2528) supporting public policy reform by challenging the 
federal statute through the reclassification of marijuana and/or decriminalization under 
federal law. On January 27, 2017, H.R. 714: Legitimate Use of Medicinal Marijuana Act 
(LUMMA) was introduced to legally allow states to identify an appropriate use of 
medical cannabis without fear of criminal federal prosecution. Also in support of policy 
reform is H.R. 2528: Respect States and Citizen’s Rights Act of 2017 (introduced in the 
House). If passed, the bill will amend federal law by decriminalizing the possession, 
distribution, and cultivation of state-regulated medical marijuana. As a result, the FFDCA 
(21 U.S.C 301) would no longer supersede state law allowing for the therapeutic use of 
medical cannabis.  
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Therefore, physicians who provide written recommendations for their patients 
will be able to legally obtain medicinal cannabis as treatment for chronic illness. Patients 
will be allowed to possess, transport, and conduct activities related to medical cannabis 
within the confines of their states’ medical cannabis laws. Moreover, according to H.R. 
2528 (2017), no provision of the FFDCA shall prohibit or otherwise restrict an entity 
authorized by a state or local government, in a state in which the possession and use of 
marijuana for medical purposes is legal, from producing, processing, or distributing 
marijuana for such purpose. As a result, H.R. 2528 has the potential to allow state-
regulated medical cannabis dispensaries and patients to lawfully conduct business. It will 
allow dispensaries to cultivate, possess, and distribute medical marijuana legally under 
both federal and state law.  
However, influence and regulation continue to stem from Gonzales v. Raich 
(2005) to regulate federal, state, and local laws regarding state-legalized medical 
cannabis programs. The FDA has the power to regulate and classify controlled substances 
and/or drugs based on medicinal value and a therapeutic treatment option. Moreover, case 
law precedent continues to influence the Drug Enforcement Administration (DEA; 2019) 
and its enforcement of the federal CSA. The Supreme Court of the United States 
(Supreme Court) held that the power vested in Congress by United States Constitution 
Article I, § 8, included the power to prohibit the local cultivation and use of cannabis, 
even though such cultivation and use was in compliance with California law (Gonzales v. 
Raich, 2005). Additionally, this case overruled the State of California’s Compassionate 
Use Act 1996. As a result, state laws regarding the decriminalization of medical 
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marijuana use for patients who possess state-approved physician recommendations do not 
receive legal protection under this act because federal law supersedes state law.  
In June 2011, James M. Cole, Deputy Attorney General of the U.S. Department of 
Justice (DoJ), established the Cole Memorandum, creating more gray areas regarding 
medical cannabis (DoJ, 2013). The memo served as guidance to federal prosecutors 
concerning the enforcement of cannabis under the CSA. This included updates and 
guidance for state initiatives legalizing marijuana under state law for the possession and 
regulation of marijuana production, processing, and sale, including information for law 
enforcement and DoJ attorneys regarding enforcement efforts and resources. Therefore, 
as long as the states do not violate federal priorities, the federal government will allow 
the states to regulate and enforce cannabis under their individual state laws (California 
Department of Food and Agriculture, 2017; Titus, 2016). 
Contemporary Uses of Medicinal Cannabis for Therapeutic Benefits 
Until recently, medicinal cannabis was not an option for most patients. Therefore, 
it is imperative to address gaps in existing literature supporting the need for a formal 
delivery system of medicinal cannabis for the treatment of disease in the United States for 
those suffering with a medical or chronic illness. For instance, according to emerging 
research, cannabis is a viable treatment option for a number of clinical applications. 
According to NORML (2019), treatment with medicinal cannabis can be for nausea, 
glaucoma, movement disorders, appetite stimulation, dementia, GI disorders, chronic 
pain, ALS, and PTSD. In 2010, following clinical trials, the University of California 
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Center for Medicinal Cannabis Research concluded cannabis should be “first line 
treatment” for patients with serious illnesses and neuropathy (NORML, 2019).  
The struggle for regulatory recognition of the medical cannabis industry is one 
with extensive resources from the pharmaceutical industry and associated businesses, as 
all parties seek to maintain a major role in the development of medicinal cannabis. In the 
face of this legislative lack, pharmaceutical medication abuse is growing at an alarming 
rate (Substance Abuse and Mental Health Services Administration, 2017). Furthermore, 
the use of and dependence on pharmaceutical opiates is a critical public and personal 
health concern (Lucas, 2012; Scavone, Sterling, & Van Bockstaele, 2013). However, 
according to Lucas, there has been an increase in the use of medical cannabis as a 
substitute for pharmaceutical opiates. Moreover, the use of medical cannabis can help 
reduce the tolerance to and/or withdrawal from opiates (Lucas, 2012; Scavone et al., 
2013). As a result, medical cannabis has proven therapeutic in clinical settings by 
lessening patients’ chronic pain and giving them opportunity to reduce the use of 
problematic pharmaceutical opiates. Furthermore, medicinal cannabis is a demonstrated 
means of treating symptomology and management of debilitating diseases.  
According to Johannigman and Eschiti (2013), Strouse (2015), and Uritsky, 
McPherson, and Pradel (2011), hospice professionals dealing with terminally ill patients 
support the use of medicinal cannabis within a hospice facility. Uritsky et al. indicated 
90% of hospice care professionals were in agreement on legalization of cannabis, with 
the majority of participants indicating that cannabis has medicinal benefits. The use of 
medicinal cannabis within palliative care settings by oncology and advanced practice 
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nurses is another consideration. For example, patients within this type of environment 
could be suffering from cancer, a qualifying condition for many state medical cannabis 
programs. When patients are in oncology palliative care, the use of medical cannabis can 
reduce nausea and vomiting, control pain, diminish spasticity, and decrease intraocular 
pressure (Bonn-Miller et al., 2014; Johannigman & Eschiti, 2013). Because continuing 
this limited and restrictive access to medicinal cannabis has proven both ineffective and 
counterproductive, I sought to help fill the gap and provide new research that can aid in 
the regulatory transformation and possibilities for a formal delivery system for the 
treatment of disease with medicinal cannabis in the United States.  
Treatment for Patients Suffering with Terminal or Chronic Illness  
According to Cook, Lloyd-Jones, Ogden, and Bronomo (2015) and Webb and 
Webb (2014), several random trials have shown promising treatment with the use of 
medicinal cannabis for several illnesses. For instance, patients suffering with multiple 
sclerosis have shown a reduction in spasms and an improvement in sleep. Cancer patients 
undergoing chemotherapy have reported a reduction in nausea and vomiting with the use 
of medicinal cannabis (Bonn-Miller et al., 2014; Cook et al., 2015). Additionally, 
anorexia and chronic neuropathic pain respond to medicinal cannabis as a means of 
treatment to stimulate appetite and reduce pain. Druzin (2016), the Medical Director at 
Oasis Medical Centre in Windsor, Ontario, indicated that patients suffering with 
neuropathic pain, arthritic pain, and musculoskeletal chronic pain benefit from medicinal 
cannabis as a viable form of treatment. Doctors at the Centre found using medicinal 
cannabis beneficial for the treatment of fibromyalgia, nausea, appetite stimulation in 
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cancer patients, Crohn’s disease, and multiple sclerosis (Druzin, 2016). According to 
Betthauser, Pilz, and Vollmer (2015) and Krumm (2016), the use of medicinal cannabis is 
effective in treating patients suffering with posttraumatic stress disorder, as cannabis 
targets neurobiological processes and returns neurotransmitter imbalances to a state of 
homeostasis (Krumm, 2016). 
Statutory Basis for Delivery System Currently Established by the United States 
Government 
In 1996, California voters passed Proposition 215, making California the first 
state to legalize the use of medicinal cannabis (NORML, 2019; Titus, 2016). Since then, 
more than 25 states and the District of Columbia have legalized and implemented 
medicinal cannabis programs. In 2009, DoJ Attorney General Eric Holder issued 
memoranda outlining medicinal cannabis programs within the United States (Titus, 
2016). According to the Ogden Memorandum, the use of federal resources should not be 
utilized to penalize person(s) who use medicinal cannabis as long as they are in 
compliance with state-specific medicinal cannabis laws (Titus, 2016). As a result, there is 
renewed attention on the use of medicinal cannabis as a treatment option. According to 
Baron (2015), Butler (2013), and Titus (2013), theories of federal “conflict” preemption 
are roadblocks to state medical cannabis programs, as the federal government has the 
power to delay legislation implementation. Thus, the Attorney General may sue the state 
in federal court for an injunction halting the state from implementing and/or providing 
state-legalized medicinal cannabis programs. 
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One federal statute regarding medicinal cannabis is the FFDCA: “The term ‘drug’ 
means articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention 
of disease in man . . . and articles (other than food) intended to affect the structure or any 
function of the body of man” (21 U.S.C. § 900, 2007). The FDA has the authority to 
regulate controlled substances and classify each drug according to a “schedule,” based on 
medicinal properties and/or value. Currently, the FDA classifies medicinal cannabis as a 
Schedule 1 narcotic with no medicinal properties, something echoed by the CSA (1970) 
in deeming marijuana a Schedule 1 controlled substance. To warrant Schedule 1 
classification, a drug must have a potential risk of abuse, lack acceptable safety standards, 
and have no accepted medical value. As a result, the Drug Enforcement Administration 
(DEA) is required to complete an investigation and prosecution for violations of 
controlled substance laws within interstate and international levels (DoJ, 2017).  
Gonzales v. Raich (2005) is the most recent case and precedence decided by the 
Supreme Court regarding the use of state-regulated medicinal cannabis and federal law. 
According to Article IV, the Constitution and laws made in the pursuance thereof are the 
supreme law of the land, with federal law governing in case of conflict between federal 
and state laws. The federal government’s continued support of the CSA appears to be 
relevant given case precedence regarding medical marijuana cases decided by the 
Supreme Court. According to the CSA, prohibition of marijuana manufacture and 
possession, as applied to intrastate manufacture and possession for medical purposes 
under California law, should not exceed Congress’ power under Federal Constitution’s 
commerce clause (Art. I, § 8, cl. 3). Therefore, patients living in California who were 
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otherwise protected under the state’s approved medical cannabis program were not able 
to obtain injunctive and/or declaratory relief from the CSA. As a result, the Supreme 
Court established precedent with this case and held that the power vested in Congress by 
the Constitution included the prohibition of marijuana use and cultivation, even if the use 
and/or cultivation was in compliance with state law (Gonzales v. Raich, 2005). 
Federal law continues to conflict with new state medical cannabis laws and 
regulations. As a result, states are challenging supremacy, the concern being whether the 
federal government will enforce the law of the land. For instance, state agencies have the 
power to establish and enforce public health and housing standards, regulate utility 
rates/practices, and govern labor and business activities (Olsen, 2009). Therefore, it is 
essential to review state regulation such as the Arizona Medical Marijuana Act (2010). 
The Arizona Department of Health Services was the state regulatory entity granted 
authority to create the program after passage of Proposition 203. The basic interpretation 
of the Arizona Medical Marijuana Act is: 
In this chapter, unless the context otherwise requires: 1. “Allowable amount of 
marijuana” (a) With respect to a qualifying patient, the “allowable amount of 
marijuana” means: (i) Two-and-one-half ounces of usable marijuana; and (ii) If 
the qualifying patient’s registry identification card states that the qualifying 
patient is authorized to cultivate marijuana, 12 marijuana plants contained in an 
enclosed, locked facility except that the plants are not required to be in an 
enclosed, locked facility if the plants are being transported because the qualifying 
patient is moving. (A.R.S. 36 § 2801) 
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Other states have enacted similar regulations regarding the legalization of 
medicinal cannabis. In 1996, California established the Compassionate Use Act to 
eliminate state-level criminal penalties for the use, cultivation, and possession of 
cannabis by patients who obtained a physician’s written recommendation indicating the 
therapeutic benefits from the use of medical marijuana (California Health Safety, 1996, § 
11362.5). The Compassionate Use Act affords legal protection to patients diagnosed with 
any debilitating illness where the medical use of marijuana has been “deemed appropriate 
and has been recommended by a physician” (NORML, 2019, n.p.). Further support in the 
literature comes from the experience of foreign governments in developing delivery 
systems for medicinal cannabis. 
Delivery System Currently Established by Foreign Governments for Medicinal 
Cannabis 
Several foreign governments have established a delivery system for equal access 
to medical cannabis for the treatment of disease. Three of the most noteworthy nations at 
the forefront of medical cannabis delivery are Israel, Canada, and Australia. It appears 
Israel is one of the more progressive countries regarding medicinal cannabis, with the 
Ministry of Agriculture’s research organization building a national institute for medical 
marijuana research. Similarly, Canada has laws in place regarding individual use and 
access as well as hospital administration oversight and delivery. In 2016, Australia 




In accordance with the State of Israel Ministry of Health and Government 
Resolution 3609, the Ministry of Health created a government agency, the Medical 
Cannabis Unit, to oversee the regulation of cannabis for both research and medicinal use 
(State of Israel Ministry of Health, 2019). In 2016, an additional resolution provided the 
regulations outlined by the Minister of Health providing qualified patients with equal 
access and good-quality medical cannabis. The Medical Cannabis Unit also ensures 
physicians will be able to prescribe the correct dosage as dispensed and accessed at the 
local pharmacy (State of Israel Ministry of Health, 2019). According to the Health 
Ministry (2017), approximately 25,000 Israelis have permits to consume medicinal 
marijuana to mitigate symptoms of cancer, epilepsy, and other diseases, a number that 
appears to be growing. The Health Ministry published the Green Book documenting the 
country’s system of delivery, with international recognition (State of Israel Ministry of 
Health, 2019). 
Canada 
Canada is also at the forefront of the medicinal cannabis industry with an 
established delivery system and equal access for qualified medicinal cannabis patients. 
Qualified medicinal cannabis patients, authorized by their health care practitioner, can 
access medicinal cannabis in several ways (Government of Canada, 2019), including 
registering with licensed producers, registering with Health Canada to produce a limited 




In August 2016, the four-part Access to Cannabis for Medical Purposes 
Regulations (ACMPR) replaced the Marihuana for Medical Purposes Regulations 
(MMPR; Ministry of Health Canada, 2017). First, it established a framework for licensed 
commercial production and distribution of quality-controlled medicinal cannabis in 
secure and sanitary conditions (2017). Second, it outlined the provisions for individual 
production amount or designating another individual as the named producer of the 
medicinal cannabis. The final two parts of the ACMPR outlined transitional provisions, 
additional amendments to regulations, and Health Canada protocols as of 2016. In a 
hospital setting, the individual in charge of the hospital can allow the administration, sale, 
or delivery of medicinal cannabis to a patient or an individual responsible for the patient. 
Australia 
In October 2016, Australia established a delivery system for equal access to 
medicinal cannabis for qualified patients. According to the Australian Government 
Department of Health (2017), the Commonwealth regulates medicinal cannabis products 
through the Therapeutic Goods Administration (TGA) and the Office of Drug Control, 
thus overseeing medicinal cannabis products for therapeutic use. Administered by the 
TGA, the Australian Register of Therapeutic Goods is responsible for importing, 
supplying, and exporting marijuana from Australia (Australian Government Department 
of Health, 2017). In addition, the TGA regulates medicinal cannabis products supplied in 
Australia, with clinical trials conducted in support its use for medicinal purposes. 
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Undercurrent of Political Rhetoric and Patient Needs 
In the political realm, the federal government has established an anticannabis 
position regarding the therapeutic value of medicinal cannabis. For example, the federal 
government, under the authority of the CSA decision to override state initiatives, has 
deemed it appropriate for the DoJ DEA to carry out one of its primary responsibilities 
through “investigation and preparation for the prosecution of major violators of 
controlled substance laws operating at interstate and international levels” (DoJ, 2017). 
Therefore, the politics behind the use of medicinal cannabis for the treatment of disease 
add further stress to medical practices and administrative processes when physicians try 
to satisfy patient medical needs. As a result, there is a need for an increased 
understanding about the lack and development of a delivery system to use medicinal 
cannabis for the treatment of disease in the United States. 
Conclusion 
Chapter 2 included an overview of the existing body of literature on the 
theoretical framework, history, contemporary therapeutic uses, statutory basis for 
delivery systems, and political rhetoric verses patient needs of medicinal cannabis. The 
development of policy and regulatory transformation is essential for the establishment of 
a delivery system when treating disease and improving systems of government oversight 
for current and future policy within the US. However, in the 1930s research regarding the 
benefits of medicinal cannabis was not prevalent and therefore did not support cannabis 
as a form of therapeutic treatment (MacDonald & Pappas, 2016). Furthermore, 
propaganda and political factors by prominent members of the business community 
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created stigma and apprehension, negatively impacting medicinal cannabis use and 
leading to its eventual elimination as a therapeutic treatment of illness and disease within 
the United States (Baron, 2015; Routh, 2017). Additionally, the federal government 
established a new precedent in the 1970s, classifying marijuana a Schedule 1 narcotic 
under the CSA (Kamin, 2012; Routh, 2017). However, as documented in Chapter 2, 
current medical and scientific researchers provide evidence in support of the 
medicinal/therapeutic value of using cannabis as a treatment of disease. Over 30 states 
are establishing or have implemented laws legalizing the use of medicinal cannabis for 
qualified medical cannabis patients.  
Until recently, medicinal cannabis has not been a viable therapeutic treatment 
option for most patients. Therefore, it is time to address gaps in the literature regarding 
the need for a formal delivery system of medicinal cannabis for the treatment of disease 
in the United States. However, the federal “conflict” preemption is a roadblock to state 
medical cannabis programs (Baron, 2015; Butler; 2013; Titus, 2013), as the U.S. 
government may to hinder the implementation of legalization referenda by halting states 
from implementing and/or providing state-legalized medicinal cannabis programs. As a 
result, this study is an opportunity to change the current underlying anticannabis political 
influence. A formal delivery system in the United States would be new, as no legislators 
or government officials have yet implemented such a system for medicinal cannabis and 
the treatment of disease for improving systems of government oversight for medical 
cannabis programs and/or policies. 
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Chapter 3: Research Method 
Introduction 
Through this qualitative cross-case analysis, I explored how state-level regulatory 
efforts in medicinal cannabis provide guidance on formulating national public policies 
that are most beneficial to U.S. patients. I examined three exemplary states with the goal 
of extracting best practices for adopting a national-level policy. I used three of NORML’s 
patient-centric, evidence-based medical cannabis program core tenets as a benchmark for 
assessing the merit of each state’s medical cannabis policy: (a) access to the whole plant, 
(b) an expansive list of qualifying medical conditions, and (c) patients having a legal 
option to cultivate for personal use in their private residence (NORML, 2019). More than 
30 states have legalized the use of medicinal cannabis, creating potential conflicts with 
the federal government (Routh, 2017). The United States does not currently have a 
formal delivery system for medicinal cannabis, as the federal government has classified 
medicinal cannabis as without medicinal merit.  
NORML, a public-interest nonprofit lobby, has since 1972 advocated for the legal 
use of medicinal cannabis and provided a model supporting the rights of patients and 
physicians to use medicinal cannabis for the treatment of disease. NORML is the 
benchmark for this study because the organization lobbies Congress and state legislatures 
for more consistent and rational policies. With representatives serving as expert witnesses 
in legislative hearings, NORML assists and defends the reform of medical cannabis 
regulations for the treatment of suffering and pain. In addition, the organization provides 
public access to educational and legal research, including a 50-state legislative tracking 
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system. As such, NORML is the leading authority in the cannabis industry and was 
therefore the model for this study.  
The purpose of this study was to address the need for an increased understanding 
concerning the lack of and possibilities for the development of a delivery system to use 
medicinal cannabis for the treatment of disease in the United States. In this chapter, I 
provide the rationale for the cross-case analysis design and explain the role of the 
researcher. I illustrate the methodology for this study, including its context and criteria 
for selecting participants. After an explanation of the data collection and data analysis 
processes are issues of trustworthiness and ethical procedures. The information from this 
research study may be helpful in the creation of a formal delivery system for accessing 
medicinal cannabis that can be used as best practices across state lines, as federal law 
does not presently recognize the medicinal properties of cannabis. I used a qualitative 
cross-case study design to help fill the gap identified as a lack of existing research 
supporting an optimal medical cannabis delivery system. 
Design and Rationale 
The goal of this study was to explore the need for the development of a delivery 
system to use medicinal cannabis for the treatment of disease in the United States. 
According to Creswell (2013) and Patton (2015), a case study allows a researcher to elicit 
detailed, rich information about individuals. As the research question called for an in-
depth collection of data, including existing and secondary data such as legislative and 
public databases, websites, and documents, this was the best method for analysis. Patton 
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argued that every research study can be a case study, because scholars are analyzing 
social phenomena over time, bounded by time and place. 
As an authority in the cannabis industry, NORML served as the post of reference. 
I analyzed public databases, websites, and documents from a population of three 
exemplary state medicinal cannabis programs and compared this data with three core 
tenets of NORML’s (2019) patient-centric medical cannabis program: (a) patient access 
to the whole plant, (b) an expansive list of qualifying medical conditions, and (c) patient 
having a legal option to cultivate for personal use in their private residence. I sought to 
build perspectives by using a cross-case analysis and comparing state-implemented 
medical cannabis programs with a benchmark, authoritative coalition recommended 
patient-centric, evidenced-based medical cannabis program to analyze ideas and opinions 
regarding patient access to medicinal cannabis (NORML, 2019). The opinions, laws, and 
perspectives of each entity helped to answer the following research question:  
RQ: How do state-level regulatory efforts in medicinal cannabis provide guidance 
on formulating national public policies that are most beneficial to patients in the United 
States? 
The use of a qualitative case study design method allows a researcher to gain a 
better understanding of complex issues using open-ended questions focused on a 
phenomenon within the context of real life (Baskarada, 2014). A case study research 
design method involves the study of a single unit to gain a better understanding of the 
larger class of units (Baskarada, 2014; Patton, 2015). This design enables the researcher 
to obtain substantial insight into and understanding of the research problem (Baskarada, 
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2014; Maxwell, 2013). Therefore, a qualitative cross-case analysis research design was 
most appropriate for this study because it allowed me to analyze three of NORML’s 
patient-centric, evidence-based medical cannabis program core tenets in comparison with 
three exemplary state-medical cannabis programs. Given the theoretical basis in policy 
feedback theory, I intended to understand the policy and political experience of three 
states with remarkable programs and develop professional recommendations. This 
comparison revealed patterns and ideas regarding current and future regulatory efforts 
and policies that could benefit medicinal cannabis patients in the United States and 
illustrate how existing policies without equal access impact quality of life.  
According to Grady et al. (2013), using secondary data as a data collection 
strategy to gather substantive content can result in a substantial amount of data 
researchers can analyze and use to discover and evaluate unnoticed patterns and 
outcomes. The use of existing data assisted in the analysis of real-world utilization and 
effectiveness of medical cannabis programs and policies regarding patient access (Grady 
et al., 2013). The study did not include a pilot study or an intervention study. Next, I 
explain the role of the researcher for this study. 
Role of the Researcher 
My role as researcher in this study was to analyze existing data such as legislative 
and public databases, state government websites, and documents as the best method for 
this cross-case analysis. According to Yin (2009), cross-case analysis is a form of case 
study research in which researches use existing data not dependent upon participant-
observer data, resulting in valid, high-quality data. As Owen (2014) argued, the challenge 
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in conducting a cross-case document analysis is that it requires researcher access to 
several resources, which helps mitigate potential researcher bias.  
Document analysis is one of the four basic types of data collection, allowing the 
researcher to analyze existing data and seek clarification if needed (Creswell, 2013; 
Patton, 2015). The document analysis conducted in this study meant I did not have any 
form of personal or professional relationship with participants. According to Miles and 
Huberman (1994), it is imperative to avoid bias because it can weaken or potentially 
invalidate a research study. In this study, neither personal agenda nor bias interfered with 
the representation of collected data. To ensure the study was free of bias, I suspended 
tacit knowledge related to the subject. As such, no ethical issues such as researcher’s 
environment, conflict of interest, or power differentials threatened this study, with 
collected data further supported using proper methodology. 
Methodology 
I used Sabatier and Weible’s (2014) policy feedback theory as the theoretical lens 
for framing the research. This framework was applicable when analyzing the formation 
of policy and examining the dynamics and societal response to these policies. To 
establish the effectiveness of this evidence, I utilized a cross-case analysis and compared 
three core tenets of NORML’s medical cannabis program with three states that have 
implemented exemplary state-medical cannabis programs. As NORML is one of the 
leading authorities in the cannabis industry, the three tenets served as the foundation for 
this cross-case analysis. Rooted in a detailed discussion of politics and policy context, I 
identified the commonalities and contrasts to determine best practices. 
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Context of the Study 
This cross-case analysis is a regulatory context of three exemplary states to 
implement medical cannabis policies, as the inconsistency of regulation leaves states to 
develop their own approaches and processes. As such, the policy feedback theory serves 
as a foundation for each state’s unique approach to policy development and practice. Also 
analyzed were secondary data regarding the evidence of patient access to the whole plant 
of cannabis, which included an expansive list of qualifying medical conditions and 
patients having a legal option to cultivate for personal use in their private residence 
(NORML, 2019). Legislative and public online databases, state government websites, and 
documents were the best methods for obtaining secondary data. State government 
websites provided information on three exemplary state medical cannabis programs and 
policies. NORML’s website and three tenets served as a model, since the organization is 
the leading authority in the cannabis industry. NORML’s model patient-centric medical 
cannabis program allowed for the cross-case analysis and comparison of policy that 
includes improved structure and addresses equal access of medical cannabis for all 
patients. According to Grady et al. (2013), evidence can facilitate the identification and 
analysis of the efficiency and effectiveness of policy through the presentation of 
literature. 
Data collection came from publicly available documents and websites identified 
by NORML’s patient-centric medical cannabis program and state medical cannabis 
legislation. The data consisted of documents such as legislative archives, state 
government websites, media, cannabis coalition groups, and media statements related to 
43 
 
medicinal cannabis legislation and the topic of study. The sources of data included 
legislative history, state legislative policy records, media from cannabis coalitions, and 
organizations related to medical cannabis. Similar and/or different factors discovered in 
this review enabled comparison and contrast. 
Upon completion of the cross-case analysis, I summarized differences and made 
recommendations both in support of and refuting current state medical cannabis policies. 
A table reveals comparison and contrast of important aspects of these polices, aspects 
recommended to exclude or include, as well as those that are the same or closely aligned 
with NORML’s model. Recommendations for amendments or alternatives to policy 
based on this comparison emerged, with patterns and ideas synthesized regarding current 
and future U.S. regulatory efforts and policies and how existing policies impact equal 
access of medicinal cannabis.  
Criteria for Contributing Cases 
The unit of analysis is the focus of qualitative research. The case study sample 
came from a population of exemplary states to implement medical cannabis programs. I 
used a cross-case analysis comparing NORML as the benchmark, specifically three core 
tenets of its patient-centric medical cannabis program. According to Patton (2015), there 
are no rules for sample size in qualitative inquiry. However, when conducting this type of 
research study, it is imperative to determine the sample size necessary to provide a sound 
understanding of the purpose of the inquiry, obtaining credible data, and collecting data 
within the established timeframe (Creswell, 2013; Maxwell, 2013; Patton, 2015). For this 
study, using a small population with information-rich cases provided meaningful data and 
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credibility. Of the existing 33 state medical cannabis programs, three exemplary states 
facilitated support and defense for the effectiveness of current policies in comparison to 
quality of patient care amid having no federal model to use as a guide. As such, the 
inconsistencies have resulted in a myriad of different medicinal cannabis policies. 
The most value-oriented, information-rich case studies include current cases that 
allow a researcher to uncover an accurate, in-depth understanding of patterns or themes 
(Creswell, 2013). According to Patton (2015), a small sample size may provide 
substantial breakthroughs and understanding of many types of phenomena. Thus, the 
sample for this study was three exemplary state medical cannabis programs. Selection 
criteria were states with medical marijuana legislation in place. One risk therein is that 
states with future legislation may have improved methods, therefore creating potential 
bias among existing states. As such, subsequent states enacting policy have had the 
benefit of witnessing where others have succeeded or failed.  
Data Collection 
Qualitative data collection may come from multiple types of information and/or 
data, including observations, interviews, documents, and audiovisual materials (Creswell, 
2013; Maxwell, 2014; Patton, 2015). Data collection involved reviewing legislative 
records, memos, state government websites, cannabis coalitions, and all documents 
available on medicinal cannabis programs. I compared three of NORML’s patient-
centric, evidence-based medical cannabis program core tenets—patient access to the 
whole plant, an expansive list of qualifying medical conditions, and patients having a 
legal option to cultivate for personal use in their private residence—with three exemplary 
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state medical cannabis programs (NORML, 2019). Internet-based and hard copy data 
collection facilitated the identification of patterns and ideas regarding current and future 
regulatory efforts and policies for medicinal cannabis within the United States and how 
existing policies impact equal access. I took notes to document my thoughts, determine 
coding decisions, and form analytical memos. Ensuring a sufficient number of cases is 
necessary to achieve saturation (Rudestam & Newton, 2007). In this case, the relationship 
between sample size and saturation came from the use of three exemplary states of the 
existing 33 that have implemented medicinal cannabis programs. The next step in the 
data collection process was data analysis. 
Data Analysis 
The use of coding in support of data analysis enabled me to answer the research 
question for this study following accumulation of documents, legislation, and notes. 
Upon review of the NORML’s patient-centric medical cannabis program and current 
state-implemented cannabis programs, coding occurred. This allowed for researcher 
reflection and the opportunity to edit as needed.  
Coding stemmed from the use of NORML’s patient-centric medical cannabis 
program as a benchmark for cross-case analysis comparing state-implemented medical 
cannabis programs. A selective, or analytical, model of coding or coding scheme was 
appropriate, as it enables researchers to use one category to compare all data collected 
(Gerring, 2007; Miles & Huberman, 1994). Analysis of written artifacts and research 
occurred using selective coding as the specific model and aided in identifying key 
categories or themes (Burla et al., 2008; Creswell, 2013). The themes that emerged 
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reflected and determined the sample states’ existing policies and alignment, if any, with 
NORML’s three tenets.  
To sustain consistency and validity in this cross-case analysis, only one category, 
NORML, underwent selective coding, with the three exemplary states compared against 
NORML’s guidelines. According to Miles and Huberman (1994), the use of triangulation 
is helpful for securing corroborating evidence from multiple sources. To ensure reliability 
and validity of the analyzed data was theme triangulation and review for accuracy by the 
researcher. The process of documenting the perspective or theme established from the 
data will help provide validity to the findings. Moreover, some of the information/data 
gathered from NORML or state medical cannabis programs did follow the predominant 
theme or pattern. According to Gerring (2007), it is imperative for the researcher to report 
the negative analysis, thereby giving a realistic assessment of the phenomenon. 
Therefore, this research study included selective coding, whether the evidence was 
positive or negative. 
The NVivo software database management system was essential for data 
collection tool effectiveness. NVivo software helps a researcher secure the collected data, 
making it available via searches and themes. Upon entering the data into NVivo, themes 
began to materialize, allowing for data exploration and coding. According to Patton 
(2015), the quality and credibility of qualitative research includes data collection and data 
analysis, coding data, and identifying recurring themes that help in making meaning and 
establishing accuracy. This software served as an instrument to ensure study accuracy, as 
efficiency lies in reducing the time required for grouping data into categories, comparing 
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data form notes and transcripts, and finding coded themes (Patton, 2015). As a result, 
NVivo software assisted in the organization of data into relevant clusters, which were 
essential in the analysis. The issue of trustworthiness appears in the following section. 
Issues of Trustworthiness 
Trustworthiness of qualitative data increases through the following basic 
measures: participant criteria, unbiased question, multiple data collection, systematic 
process and data analysis, and peer review (Fenton & Mazulewicz, 2008). When 
conducting research for this study, it was imperative to have mechanisms in place to 
maintain and check for trustworthiness, quality, and credibility of the data obtained. 
According to Kornbluh (2015), the goal of trustworthiness in qualitative inquiry and 
findings has four basic elements: (a) credibility to focus on internal validity, 
(b) transferability focused on external validity, (c) dependability focused on reliability, 
and (d) conformability.  
To ensure credibility and internal validity, qualitative research methods and 
procedures proved accurate by seeking information, collecting data, ensuring 
unwarranted data did not appear the findings, and not dismissing any data. Since I 
explored several data sources and incorporated different perceptions, it was imperative to 
exercise triangulation. Additionally, ensuring triangulation of the data sources, the 
documents and policy of NORML’s patient-centric medical cannabis program, and 
several state-implemented medical cannabis programs assisted in a trustworthy 
interpretation of the data.  
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External validity comes from the transferability of a substantial amount of 
information and/or findings from one case study to another (Creswell, 2013; Patton, 
2015). Thus, I established external validity of the context regarding the need for an 
increased understanding about the lack of and possibilities for the development of a 
delivery system to use medicinal cannabis for the treatment of disease in the United 
States. Future researchers may use this information, as it is at the forefront of an 
emerging issue. For the purpose of transferability, a detailed description of the method 
was necessary. The use of a cross-case analysis in comparing three exemplary state-
implemented medical cannabis programs with three of NORML’s patient-centric, 
evidence-based medical cannabis program core tenets created variation within the 
selection process. 
To establish dependability, the researcher must fully document the process of 
inquiry and responsibility for a documented, traceable, and logical case study (Patton, 
2015). To address reliability, I included a descriptive, detailed plan regarding the research 
design and data collection techniques for the possibility of future study replication, as 
well as a discussion and evaluation for the effectiveness of the research. Triangulating 
data provides corroborating evidence and reliability for a research study (Creswell, 
2013). The use of different sources in this case study helped to establish a particular 
theme and/or perspective. 
For the purpose of confirmability, a detailed account of three exemplary state-
implemented medical cannabis programs and three of NORML’s patient-centric, 
evidence-based medical cannabis program core tenets appears in Chapter 4. Patton (2015) 
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indicated that it is essential for the researcher to maintain an awareness of potential bias 
and/or reflexivity such that personal subjectivity of researcher perceptions does not 
influence the study. Asking a series of specific questions regarding subjectivity of 
findings will ensure trustworthiness. Furthermore, all data and analysis will be available 
upon request. 
Ethical Procedures 
The role as a researcher and agent of positive social change involves following a 
code of ethics. The means of study execution must be ethical, as it gives validity to the 
results. Researchers must learn to anticipate ethical issues, resolve them, and ensure there 
are no human rights violations (Creswell, 2013). This study did not require institutional 
permission for data collection. Since this study depended upon the availability of public 
secondary/existing data, there was no need for protections for human participants. Also 
unnecessary were anonymity and/or confidentiality in data collection.  
Throughout data collection and analysis, I projected an impartial tone and showed 
no bias in the outcome. Furthermore, all documents studied are public records and freely 
available for review. Subsequently, all data and information used in this study will be 
available for future confirmation or replication of the research. Because sources could 
contradict one another, I will disclose any conflicts of interest within the discussion of 
results. 
Summary 
Chapter 3 included an explanation of qualitative case study research as a means to 
obtain information by using a cross-case analysis to collect, analyze, and provide results. 
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By comparing three states’ legislation, I addressed the need for an increased 
understanding of the lack of and need for development of a delivery system to use 
medicinal cannabis for the treatment of disease in the United States. This chapter 
included a description of the purpose of this study and the design and rationale. The role 
of the researcher in this study appeared along with the methodology, including the 
context of the study and criteria for selecting participants. Data collection and assessment 
processes provided include issues of trustworthiness in support of this study. The results 




Chapter 4: Results 
Introduction 
In this chapter are the results from this qualitative cross-case analysis. The 
purpose of this research study was to address the need for an increased understanding 
about the lack of and possibilities for development of a delivery system for medicinal 
cannabis for the treatment of disease in the United States. As policy design theory 
supports the concept that groups will either positively or negatively interpret the process 
of policy development, I used this theory in support of the study. I obtained the case 
study sample from a population of three states that implemented exemplary medical 
cannabis programs. I used three of NORML’s core tenets of the patient-centric medical 
cannabis program as the benchmark, as the organization is one of the leading authorities 
in the cannabis industry. The sample cases for cross analysis were the states of California, 
Colorado, and Nevada. The research question used to guide this study was:  
RQ: How do state-level regulatory efforts in medicinal cannabis provide guidance 
on formulating national public policies that are most beneficial to patients in the United 
States? 
In this chapter, I describe the setting and demographics and explain the need for 
this study. Data collection and data analysis occurred in such a manner so as to ensure 
trustworthiness. I also discuss the themes derived from this study.  
Setting 
A small population with information-rich cases provides meaningful data and 
credibility. Of the existing 30 state medical cannabis programs, I used three exemplary 
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states to support and defend the effectiveness of current policies in comparison to the 
quality of patient care. However, all states lacked a model to use as a guide, thus having 
to implement unique policies and regulations. States used were the states of California, 
Colorado, and Nevada as exemplary cases in comparison with three of NORML’s 
patient-centric, evidence-based medical cannabis program core tenets. There were no 
conditions that may have influenced participants or interpretation of study results. 
The three exemplary states chosen to explore current policies for this study were 
among the first 10 states to implement medical cannabis programs between 1996 and 
2000 (ProCon.org, 2019). Excluded from the study were medical cannabis programs with 
limited use and/or access. In June 2018, the Network for Public Health Law identified 16 
states that had implemented and/or enacted limited access cannabis product laws; thus, 
none merited inclusion in this study. However, California, Colorado, and Nevada had 
created a blueprint to which other states could refer when establishing their medical 
marijuana programs.  
California was the first state to legalize cannabis for medicinal purposes, and the 
existing program serves as a strong advocate for patients. According to Americans for 
Safe Access (2018), California is the leader in the cannabis industry and is the best place 
in the country for patients’ legal protections and access. The state also removed the sales 
and use tax on medical cannabis and improved regulations for the manufacture of 
cannabis products. Since 2014, Colorado has provided safe and legal access to medical 
cannabis patients. In this, patients are able to easily obtain medical cannabis due minimal 
zoning regulations, making dispensaries widely accessible. Further, patients can receive 
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discount medical cannabis due to financial hardship. Nevada has also established a strong 
medical cannabis program that demonstrates the value of keeping medical and adult use 
programs legislatively separate. As a result, patients are able to obtain medicinal cannabis 
with a very high product safety rating. Cornerstone to these participating states is the 
complex perception of policy subsystems requiring nontraditional thinking, something 
further supported by policy feedback theory (Weible et al., 2011).  
Demographics 
I chose the participants of the study due to the exemplary nature of each state’s 
existing programs. Each year, Americans for Safe Access reviews states’ medical 
cannabis program based on how well the current law and regulations accommodate 
patient needs. California, Colorado, and Nevada scored in the highest percentile for 
accommodating patient needs when compared to all other states that have implemented a 
medical cannabis program (Americans for Safe Access, 2018). 
Data Collection 
I compared the exemplary state medical cannabis programs with three of 
NORML’s (2019) patient-centric, evidence-based medical cannabis program core tenets: 
(a) patient access to the whole plant, (b) an expansive list of qualifying medical 
conditions, and (c) patients having a legal option to cultivate for personal use in their 
private residence. Data collection involved reviewing legislative records, memos, state 
government websites, cannabis coalitions, and documents available on medicinal 
cannabis programs and equal access. Information was readily available from each state, 
with all data easily located and transparent. I compared Internet-based and hard copy data 
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for patterns concerning existing regulatory efforts and policies for medicinal cannabis. 
All data collected are available for public view. I took notes in the form of analytical 
memos, subsequently retaining all recorded all data and researcher notes on a cloud-
based system. No variations existed between data collected and the plan presented in 
Chapter 3 and I encountered no unusual circumstances during data collection. 
Data Analysis 
In the analysis process, I reviewed three of NORML’s patient-centric medical 
cannabis program’s core tenets as a benchmark against California, Colorado, and 
Nevada’s state-implemented medical cannabis programs. I used selective coding to 
compare one category to data collected (Gerring, 2007; Miles & Huberman, 1994). Using 
NVivo to inductively move coded units to a larger representation, I entered the three 
tenets and three participating states’ policies into the program for analysis. I used this 
software as an instrument to maintain accuracy. I examined the data entered, coded via 
two cycles and analyzed as NVivo produced patterns for the cross-case analysis (results 
appear in Table 1). The process of coding data included a review/analysis of each coded 
word, phrase, section, and theme in relation to the research theory. Cases/nodes were 
clustered into substantive categories to include the three exemplary state policies and 
NORML’s three core tenets. The themes that emerged reflected the participant states’ 
existing policies and alignment, if any, with NORMLs three tenets. I secured 
corroborating evidence from the three states to ensure accuracy.  
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Evidence of Trustworthiness 
Practices to ensure trustworthiness, quality, and credibility guided this study. 
According to Kornbluh (2015), achieving trustworthiness in qualitative inquiry and 
analysis requires the use of four basic factors: (a) credibility focused on internal validity, 
(b) transferability focused on external validity, (c) dependability focused on reliability, 
and (d) conformability. Credibility and internal validity emerged from seeking 
information, collecting data, including no unwarranted data in the findings, and 
dismissing no valuable data. I made no adjustments from the plan presented in Chapter 3. 
Because I explored several data sources and incorporated different perceptions, 
triangulation of NORML’s patient-centric medical cannabis program and the three 
participating states further ensured trustworthiness. I have provided a detailed description 
of the method to ensure transferability of results. Since all data collected came from 
publicly available documents, achieving trustworthiness is easier, as future researchers 
may use this study to further the existing body of literature. 
I established dependability and confirmability by documenting the process of 
inquiry and responsibility, thus making it traceable and logical (Patton, 2015). Future 
researchers may be able to confirm and replicate the results of this study. I made no 
adjustments to the descriptive detailed plan regarding the research design and data 
collection techniques provided in Chapter 3. Trustworthiness also came from maintaining 




The cross-case analysis process led to the results of this study in support of the 
following research question:  
RQ: How do state-level regulatory efforts in medicinal cannabis provide guidance 
on formulating national public policies that are most beneficial to patients in the United 
States? 
I established themes by comparing NORML’s three core tenets against each of the 
three participating states’ existing medicinal cannabis programs. Policy feedback theory 
further supported this research, as it incorporates policy feedback and the multitude of 
effects it provides. As Sabatier and Weible (2014) posited, the power of groups affects 
political agendas, systems of governance, and future policies. Policy feedback theory was 
appropriate this study as it defends the pattern of an individual’s preferences and choices 
as largely shaped by policies. According to policy feedback theory, researchers address 
individual concepts and their connection with others, leading to the evolution of policy. 
This hands-on theory centers on the acquisition of knowledge (Sabatier & Weible, 2014). 
As such, policy feedback theory supported the customary beliefs denoted by established 
policies impacting patients who rely on medicinal cannabis for the treatment of disease, 
thus meriting a sound delivery system in the United States (Mettler & SoRelle, 2014). 
The following sections provide an illustration of cross-case comparison (results appear in 
Table 1).  
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NORML’s Core Tenets 
Three primary tenets from NORML served as the benchmark in this study. 
According to the first, access to whole-plant cannabis, “patients must be legally able to 
obtain and possess herbal formulations of whole-plant cannabis that may be administered 
via inhalation/vaporization; their therapeutic choices must not be limited solely to orally 
administered cannabis-derived extracts, oils, or pills” (NORML, 2019, n.p.). Wide 
latitude for doctors to decide treatment regimens, the second core tenet, means “the 
approved list of qualifying conditions must be expansive and must allow physicians the 
option to recommend cannabis therapy for the treatment of chronic pain” (NORML, 
2019, n.p.). NORML’s (2019) third core tenet, personal cultivation rights, says that 
“registered patients ought to have the legal option to cultivate personal use quantities of 
cannabis in their own private residence” (n.p.). I analyzed the three states’ existing 
policies against the benchmark of NORML, as illustrated next. 
California Policy and NORML’s First Core Tenet 
California’s policy for access to whole-plant cannabis for medical patients is “the 
voluntary registry issues ID cards that offer protection from arrest for patients and 
caregivers in possession of no more than eight ounces of useable cannabis. However, 
currently there are no possession limits specified; the amount must be “consistent with 
the patient’s needs” that “has been deemed appropriate and has been recommended by a 
physician” (California Department of Public Health, 2018). When compared to 
NORML’s first core tenet for access to whole-plant cannabis, the results indicate a value 
match of one. More specifically, the match is not exact, as California’s policy has only 
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partial alignment with NORML’s first tenet. California Department of Public Health 
states that patients:  
[C]an cultivate no more than six mature or twelve immature plants. However, 
there are no cultivation limits specified under state law, but local ordinances can 
limit or ban medical cultivation. Furthermore, qualified patients are exempt from 
state licensing requirements under MMRSA, if they cultivate 100 square feet or 
less of medical cannabis. Primary caregivers serving up to five qualified patients 
may cultivate up to 500 square feet of medical cannabis without a state license. 
Cities and counties retain the right to license, regulate or ban medical cannabis 
cultivation. (2018, n.p.) 
The policy feedback theory represents policies intended to support patients in the 
United States who need medicinal cannabis and who rely on a sound delivery system 
(Mettler & SoRelle, 2014). However, current policies in the state of California limiting 
access, such as local ordinances permitting the regulation or ban of the cultivation of 
cannabis, restrict patient access. Following cross-examination against the benchmark, a 
proportion of California’s policy align with NORML’s (2019) first core tenet, access to 
whole-plant cannabis. 
Colorado Policy and NORML’s First Core Tenet 
Colorado’s existing policy, which includes access to whole plant-cannabis, allows 
a “Medical Marijuana Registry Identification Card, or that patient’s primary caregiver 
who has been identified on the patient’s Medical Marijuana Registry Identification Card, 
to possess no more than two (2) ounces of a usable form of marijuana” (State of 
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Colorado, 2018). In comparison to NORML’s (2019) first core tenet for access to whole-
plant cannabis, the results indicate a value match of one, as Colorado’s policy has a 
limited alignment with NORML’s first tenet. Colorado’s existing policy limits patient 
access, with policy feedback theory defending the diverse phenomena of policies and 
regulatory efforts impacting patient access to medicinal cannabis. When cross-examined 
against the benchmark, a proportion of Colorado’s policy aligns with NORML’s (2019) 
first core tenet. 
Nevada Policy and NORML’s First Core Tenet 
Nevada’s existing policy for access to whole-plant cannabis is: 
[T]wo and one-half ounces of usable marijuana and/or a maximum allowable 
quantity of edible marijuana products and marijuana-infused products as 
established by regulation of the Division in any one 14-day period. Can only 
purchase from designated dispensary (can change every 30 days). (Nevada 
Division of Public and Behavioral Health, 2018, n.d.) 
Comparison results to NORML’s first core tenet for access to whole-plant cannabis 
indicate a value match of one. More specifically, Nevada’s policy suggests limited 
alignment with NORML’s first tenet. With Nevada’s policy limiting access to a 14-day 
period and the multifaceted factors of policy subsystems, policy feedback theory is 
paramount, as patients naturally rely on heuristic thinking and trust the social paradigm of 
policy design. Patients’ knowledge and familiarity is crucial, as public policy largely 
involves fundamental processes (Weible et al., 2011). In cross examination against the 
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benchmark, a proportion of Nevada’s policy matched against NORML’s (2019) first core 
tenet. 
As illustrated in Chapter 2, qualified patients may possess and cultivate medicinal 
cannabis without the fear of criminal federal prosecution as long as they remain 
compliant with state-established medicinal cannabis program laws, rules, and regulations 
(Freisthler & Gruenewald, 2014). Each state’s regulated programs permit patients to use 
and access medicinal cannabis through dispensaries regulated by state and local 
jurisdictions (Freisthler & Gruenewald, 2014). Patients are allowed to possess, transport, 
and conduct activities related to medical cannabis within the confines of their state’s 
medical cannabis laws. According to H.R. 2528 (2017), no provision of the FFDCA shall 
prohibit or otherwise restrict an entity authorized by a state or local government, in a state 
in which the possession and use of marijuana for medical purposes is legal, from 
producing, processing, or distributing marijuana for such purpose. However, the Supreme 
Court held that the power vested in Congress by United States Const. Art. I, § 8 overruled 
the state of California’s Compassionate Use Act (1996). As a result, California state laws 
regarding the decriminalization of medical marijuana use for patients who possess state-
approved physician recommendations are not legally protected under this act, as federal 
law supersedes state law.  
California Policy and NORML’s Second Core Tenet 
California’s existing program also includes a wide latitude for doctors to decide 
treatment regimens, with qualifying conditions including “anorexia, arthritis, cachexia, 
cancer, chronic pain, HIV or AIDS, glaucoma, migraine, persistent muscle spasms, 
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severe nausea, seizures and any debilitating illness where the medical use of marijuana 
has been deemed appropriate and has been recommended by a physician” (California 
Department of Public Health, 2018, n.p.). In comparison to NORML’s (2019) second 
core tenet providing wide latitude for doctors to decide treatment regimens, results of this 
cross-case analysis represent a value match of one. More precisely, California’s policy 
suggests partial alignment with NORML’s second tenet. 
California’s specific policy has a focus on qualifying conditions for determining 
doctors’ latitude to decide treatment. As supported by the policy feedback theory, 
physicians in the state of California have the opportunity to recommend medicinal 
cannabis to patients with specified conditions. This aligns with the framework of public 
policy, as patients rely on empirical thinking to decipher the complex subsystems of 
policy design. In cross-examination to the benchmark, California policy results in a 
partial match against NORML’s (2019) second core tenet. 
Colorado Policy and NORML’s Second Core Tenet 
Colorado’s current policy incorporates wide latitude for doctors to decide 
treatment regimens. The qualifying conditions include: 
[C]hronic nervous system disorders, post-traumatic stress syndrome and 
debilitating medical conditions are defined as cancer, glaucoma, and infection 
with or positive status for human immunodeficiency virus. Chronic or debilitating 
disease or medical condition other than HIV infection, cancer or glaucoma; or 
treatment for such conditions, which produces for a specific patient one or more 
of the following, and for which, in the professional opinion of the patient’s 
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physician, such condition or conditions may reasonably be alleviated by the 
medical use of marijuana: chronic nervous system disorders; post-traumatic stress 
syndrome; cachexia; severe pain; severe nausea; seizures, including those that are 
characteristic of epilepsy; or persistent muscle spasms, including those that are 
characteristic of multiple sclerosis. (State of Colorado, 2019, n.p.)  
In comparison to NORML’s (2019) second core tenet for providing wide latitude for 
doctors to decide treatment regimens, results of this cross-case analysis represent a value 
match of one. More specifically, a limited part of Colorado’s policy aligns with 
NORML’s second tenet. 
Colorado’s policy has a focus on qualifying conditions for determining doctors’ 
latitude to decide treatment as: 
[C]hronic nervous system disorders or post-traumatic stress syndrome; or 
debilitating medical conditions are defined as cancer, glaucoma, and infection 
with or positive status for human immunodeficiency virus. Chronic or debilitating 
disease or medical condition other than HIV infection, cancer or glaucoma; or 
treatment for such conditions, which produces for a specific patient one or more 
of the following, and for which, in the professional opinion of the patient’s 
physician, such condition or conditions may reasonably be alleviated by the 
medical use of marijuana: chronic nervous system disorders; post-traumatic stress 
syndrome; cachexia; severe pain; severe nausea; seizures, including those that are 
characteristic of epilepsy; or persistent muscle spasms, including those that are 
characteristic of multiple sclerosis. (State of Colorado, 2019, n.p.)  
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In cross-examination to the benchmark, Colorado’s policy reveals a limited match 
against NORML’s (2019) second core tenet, a list of qualifying medical conditions. The 
intricate subsystems of policy design and the reality that people inherently interpret 
policy is a social paradigm. Patients rely on familiarity and existing knowledge when 
viewing policies as positive or negative. As supported by policy feedback theory, patients 
also rely on their physician for appropriate therapies and medicine; however, current state 
policies limit both patients and physicians.  
Nevada Policy and NORML’s Second Core Tenet 
Nevada’s current policy gives doctors freedom to decide treatment regimens for 
qualifying conditions including “AIDS, cachexia, cancer, glaucoma, post-traumatic stress 
disorder (PTSD), persistent muscle spasms or seizures, severe nausea or pain, and other 
conditions are subject to approval” (Nevada Division of Public and Behavioral Health, 
2018, n.p.). In comparison to NORML’s (2019) second core tenet, results of this cross-
case analysis represent a value match of one. More precisely, Nevada’s policy has limited 
alignment with NORML’s second tenet. 
Nevada’s specific policy focuses on qualifying conditions for determining 
doctors’ latitude to decide treatment, which subsequently affects patients amid the 
complex process of policy design. As such, policy feedback theory is in support of the 
idea that individuals largely base decisions on the social constructs of groups, especially 
concerning multifaceted process of policy creation. In cross-examination to the 




According to Maxwell and Mendelson (2016), individual states determine 
medicinal cannabis regulation with regard to criteria of who can recommend and/or 
prescribe medicinal cannabis and who can become a qualified patient of the program. 
Therefore, physicians who provide written recommendations for their patients will be 
able to legally obtain medicinal cannabis as treatment for chronic illness. Following 
clinical trials in 2010, the Center for Medicinal Cannabis Research (2017) concluded that 
cannabis should be “first line treatment” for patients with serious illnesses and 
neuropathy. As such, medical cannabis treatment continues to be the answer for patients 
suffering with chronic/debilitating medical conditions (Betthauser et al., 2015; Carter, 
2013; Hill, 2015).  
California Policy and NORML’s Third Core Tenet 
California’s current policy incorporates personal cultivation rights, as the patient:  
[C]an cultivate no more than six mature or twelve immature plants. However, 
there are no cultivation limits specified under state law, but local ordinances can 
limit or ban medical cultivation. Furthermore, Qualified Patients are exempt from 
state licensing requirements under MMRSA, if they cultivate 100 square feet or 
less of medical cannabis. Primary Caregivers serving up to five Qualified Patients 
may cultivate up to 500 square feet of medical cannabis without a state license. 
Cities and counties retain the right to license, regulate or ban medical cannabis 
cultivation. (California Department of Public Health, 2018, n.p.)  
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In comparison to NORML’s (2019) third core tenet, the results revealed a value match of 
one. More specifically, a section of California’s policy aligns with NORML’s third tenet, 
although limited. 
While the state specifies no cultivation limits, local ordinances may dominate. As 
the policy feedback theory asserts, citizenship results from the power of groups, political 
agendas, and systems of governance, thus affecting future policies. As such, this theory is 
in strong support of an individual’s preferences and decisions largely molded by policies. 
In turn, patients in the state of California are limited concerning cultivation rights. In 
cross-examination to the benchmark, California’s policy results in a limited match against 
NORML’s (2019) third core tenet. 
Colorado Policy and NORML’s Third Core Tenet 
According to Colorado’s current policy for personal cultivation rights: 
[P]atients (or their primary caregivers) may cultivate no more than six marijuana 
plants, with three or fewer being mature, flowering plants that are producing a 
usable form of marijuana. Not more than six (6) marijuana plants, with three (3) 
or fewer being mature, flowering plants that are producing a usable form of 
marijuana. Patients and primary caregivers who possess more than two ounces or 
six plants have an affirmative defense in court after they have been arrested if the 
amount they have is “medically necessary to address the patient’s debilitating 
medical condition.” Patients who have a doctor’s recommendation to use medical 
cannabis but who have not obtained a Registry Identification Card also have an 
affirmative defense in court. (State of Colorado, 2018, n.p.)  
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In comparison to NORML’s (2019) third core tenet, study results showed a value 
match of one. More precisely, part of Colorado’s policy aligns with NORML’s third 
tenet, although limited. 
In cross-examination to the benchmark, Colorado’s policy results in a limited 
match against NORML’s third core tenet. Policy feedback theory comprises three distinct 
aspects: the independence of these three aspects, the role of conjunction between these 
three concepts, and the solution correspondence resulting in policy evolution. Policy 
feedback theory is fundamental, as this theory is essentially heuristic while strongly 
relying on the acquisition of knowledge (Sabatier & Weible, 2014) 
Nevada Policy and NORML’s Third Core Tenet 
Nevada’s existing policy defines personal cultivation rights as: 
[T]welve marijuana plants, irrespective of whether the marijuana plants are 
mature or immature. Limits on home cultivation if patients reside within 25-miles 
of an operating dispensary. However, patients who are cultivating specific strains 
of cannabis not provided by a local dispensary may continue to engage in the 
home cultivation of such strains. Patients who have an established history of 
cultivating medical cannabis prior to July 1, 2013, also may continue to do so 
until March 31, 2016. (Nevada Division of Public and Behavioral Health, 2018, 
n.p.) 
In comparison to NORML’s (2019) core tenet, the findings determined a value match of 




Although Nevada’s existing policies were to develop structure and provide 
benefits, policy feedback theory clearly illustrates how the dynamics of policy design 
impact people on individual and group levels (Mettler & SoRelle, 2014; Sabatier & 
Weible, 1999). The policy feedback theory supports the intent of policy design is to 
create increasing returns on prior commitments that also promote continued efforts 
(Cairney, 2012; Pierson, 2002). In cross-examination to the benchmark, Colorado’s 
policy results in a partial match against NORML’s (2019) second core tenet. 
As illustrated in Chapter 2, the California Compassionate Use Act (1996) 
eliminated criminal state-level penalties for the use, cultivation, and possession of 
cannabis (California Health Safety, 1996). Patients diagnosed with any debilitating illness 
for which the medical use of marijuana has been “deemed appropriate and has been 
recommended by a physician” receive legal protection under this Act (NORML, 2019, 
n.p.). However, the Supreme Court held that the power vested in Congress included that 
to prohibit the local cultivation and use of cannabis, even though such cultivation and use 
was in compliance with California law (Gonzales v. Raich, 2005). If the legislative bill in 
support of policy reform, H.R. 2528 Respect States and Citizens’ Rights Act of 2017 (as 
introduced in the House) passes, it will amend federal law by decriminalizing the 
possession, distribution, and cultivation of state-regulated medical marijuana.  
The results of this study have no discrepant cases and are void of nonconfirming 
data. Table 1 represents values matched against NORML as the benchmark and the states 





California, Colorado, and Nevada’s Provisions in Comparison to NORML 
Tenet California Colorado Nevada NORML 
1: Access to 
whole-plant 
cannabis 
“The voluntary registry 
issues ID cards that offer 
protection from arrest for 
patients and caregivers in 
possession of no more than 
eight ounces of useable 
cannabis. However, 
currently there are no 
possession limits specified; 
the amount must be 
“consistent with the 
patient’s needs,” that has 
been deemed appropriate 
and has been recommended 
by a physician" (California 
Department of Public 
Health, 2018). 
“Medical Marijuana Registry 
Identification Card, or that 
patient’s primary caregiver 
who has been identified on 
the patient’s Medical 
Marijuana Registry 
Identification Card, to 
possess no more than two (2) 
ounces of a usable form of 
marijuana” (State of 
Colorado, 2018). 
“Two and one-half 
ounces of usable 
marijuana and/or a 
maximum allowable 
quantity of edible 
marijuana products and 
marijuana-infused 
products as established 
by regulation of the 
Division in any one 14-
day period. Can only 
purchase from designated 
dispensary (can change 
every 30 days)” (Nevada 
Division of Public and 
Behavioral Health, 2018). 
“Patients must be 
legally able to obtain 
and possess herbal 
formulations of 
whole-plant cannabis 
that may be 
administered via 
inhalation/vaporizati
on; their therapeutic 
choices must not be 
limited solely to 
orally administered 
cannabis-derived 










program also includes a 
wide latitude for doctors to 
decide treatment regimens 
and provides qualifying 
conditions to include 
anorexia, arthritis, 
cachexia, cancer, chronic 
pain, HIV or AIDS, 
glaucoma, migraine, 
persistent muscle spasms, 
severe nausea, seizures and 
any debilitating illness 
where the medical use of 
marijuana has been 
"deemed appropriate and 
has been recommended by 
a physician" (California 
Department of Public 
Health, 2018). 
Colorado’s current policy 
incorporates a wide-latitude 
for doctors to decide 
treatment regimens. The 
qualifying conditions include 
“chronic nervous system 
disorders, post-traumatic 
stress syndrome and 
debilitating medical 
conditions are defined as 
cancer, glaucoma, and 
infection with or positive 
status for human 
immunodeficiency virus. 
Chronic or debilitating 
disease or medical condition 
other than HIV infection, 
cancer or glaucoma; or 
treatment for such 
conditions, which produces 
for a specific patient one or 
more of the following, and 
for which, in the professional 
opinion of the patient’s 
physician, such condition or 
conditions may reasonably be 
alleviated by the medical use 
of marijuana: chronic 
nervous system disorders; 
post-traumatic stress 
syndrome; cachexia; severe 
pain; severe nausea; seizures, 
including those that are 
characteristic of epilepsy; or 
persistent muscle spasms, 
including those that are 
characteristic of multiple 
sclerosis (State of Colorado, 
2018). 
Nevada’s current policy 
includes a wide-latitude 
for doctors to decide 




“AIDS, cachexia, cancer, 
glaucoma, post-traumatic 
stress disorder (PTSD), 
persistent muscle spasms 
or seizures, severe nausea 
or pain, and other 
conditions are subject to 
approval” (Nevada 
Division of Public and 
Behavioral Health, 2018). 
“The approved list of 
qualifying conditions 
must be expansive 
and must allow 
physicians the option 
to recommend 
cannabis therapy for 






Table 1 Continued 




The state of California’s 
current policy incorporates 
personal cultivation rights 
as the patient “can cultivate 
no more than six mature or 
twelve immature plants. 
However, there are no 
cultivation limits specified 
under state law, but local 
ordinances can limit or ban 
medical cultivation. 
Furthermore, Qualified 
Patients are exempt from 
state licensing requirements 
under MMRSA, if they 
cultivate 100 square feet or 
less of medical cannabis. 
Primary Caregivers serving 
up to five Qualified 
Patients may cultivate up to 
500 square feet of medical 
cannabis without a state 
license. Cities and counties 
retain the right to license, 
regulate or ban medical 
cannabis cultivation” 
(California Department of 
Public Health, 2018). 
Colorado’s current policy for 
personal cultivation rights 
encompass “patients (or their 
primary caregivers) may 
cultivate no more than six 
marijuana plants, with three 
or fewer being mature, 
flowering plants that are 
producing a usable form of 
marijuana. Not more than six 
(6) marijuana plants, with 
three (3) or fewer being 
mature, flowering plants that 
are producing a usable form 
of marijuana. Patients and 
primary caregivers who 
possess more than two 
ounces or six plants have an 
affirmative defense in court 
after they have been arrested 
if the amount they have is 
"medically necessary to 
address the patient’s 
debilitating medical 
condition." Patients who 
have a doctor’s 
recommendation to use 
medical cannabis but who 
have not obtained a Registry 
Identification Card also have 
an affirmative defense in 
court” (State of Colorado, 
2018). 
The state of Nevada’s 
existing policy for 
personal cultivation rights 
is defined as “twelve 
marijuana plants, 
irrespective of whether 
the marijuana plants are 
mature or immature. 
Limits on home 
cultivation if patients 
reside within 25-miles of 
an operating dispensary. 
However, patients who 
are cultivating specific 
strains of cannabis not 
provided by a local 
dispensary may continue 
to engage in the home 
cultivation of such 
strains. Patients who have 
an established history of 
cultivating medical 
cannabis prior to July 1, 
2013, also may continue 
to do so until March 31, 
2016” (Nevada Division 
of Public and Behavioral 
Health, 2018). 
“Personal cultivation 
rights’ and is 
described as 
‘registered patients 
ought to have the 
legal option to 
cultivate personal 
use quantities of 




In response to the research question “How do state-level regulatory efforts in 
medicinal cannabis provide guidance on formulating national public policies that are 
most beneficial to patients in the United States?” the assessment results were notable due 
to the inconsistency across the three exemplary states, which did not fully align with 
NORML’s three core tenets. Furthermore, current policy does not support the lack of 
access and benefits to patients requiring medical cannabis to treat disease in the United 
States. Therefore, current state policies do not represent the therapeutic and/or medical 
value of medical cannabis for patient suffering with diseases in the US. As a result, the 
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lack of recognition further prevents patients’ access and physicians’ ability to treat with 
medical cannabis. Furthermore, policy feedback theory supports the systematic method to 
appropriate benefits to policy recipients or target groups in groups versus as individuals 
(Maltby, 2017).  
Conclusion 
Chapter 4 included the results of this qualitative cross-case analysis research 
study addressing the need for an increased understanding about the lack of and 
possibilities for the development of a delivery system to use medicinal cannabis for the 
treatment of disease in the United States. Three states with exemplary medical cannabis 
laws—California, Colorado, and Nevada—served as this study sample population. Three 
core tenets of the patient-centric medical cannabis program of NORML, one of the 
leading authorities in the cannabis industry, served as a benchmark. The research 
question “How do regulatory efforts in medicinal cannabis shed light on what is most 
advantageous in policies that benefit patients in the United States?” guided this study. 
The policy feedback theory further supported the importance of the need for developing a 
delivery system to use medicinal cannabis for patients in the United States. A discussion 
of the setting and demographics illustrated the importance of this study. Descriptions of 
the data collection and analysis processes provided evidence of trustworthiness, with 




Chapter 5: Conclusions and Recommendations 
The medicinal value of cannabis for U.S. patients suffering from disease is 
becoming more widely known and increasingly applicable, yet existing laws and policies 
continue to limit access. The purpose of this cross-case analysis was to address the need 
for an increased understanding about the lack of and possibilities for development of a 
delivery system to use medicinal cannabis for the treatment of disease for patients in the 
United States. The following research question guided this study:  
RQ: How do state-level regulatory efforts in medicinal cannabis provide guidance 
on formulating national public policies that are most beneficial to patients in the United 
States? 
The assessment included an analysis of three exemplary states’ existing laws and 
policies against a benchmark, NORML, the leading authority in medicinal cannabis. I 
used policy feedback theory for the supporting framework. According to this theory, 
groups of people naturally interpret the concept of policy as positive or negative based on 
heuristic thinking, especially concerning the multifaceted subsystems involved. A 
qualitative cross-case analysis served as the preferred methodology and design because of 
the nature of participants. Data collected from the sample population and the benchmark 
case were publicly available documents, so a triangulated cross-case analysis served as 
the most compelling method to obtain results. The comparison of NORML’s three core 
tenets to policies in California, Colorado, and Nevada showed that patient access to the 
whole plant of cannabis is restricted, with policies varying from state to state. With this 
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study, I sought to promote consideration for the development of a delivery system in the 
United States to use medicinal cannabis for the treatment of disease.  
Purpose 
The purpose of this study was to explore the lack of and possibilities for the 
development of a delivery system to use medicinal cannabis for the treatment of disease 
in the United States. Because the US does not have a formal delivery system for medical 
cannabis, this study served to support the need for continued research at the state level for 
initiatives and system possibilities. The comparison of three tenets from the leading 
cannabis authority, NORML, to three exemplary states’ policies allowed me to identify 
the need for a uniform delivery system to support patients in the United States who 
depend on cannabis for medical purposes. Patients will benefit from a change in laws and 
uniform policy for the transportation and delivery system of medicinal cannabis by 
having access to medicinal cannabis without fear of arrest or federal criminal 
prosecution. The recommendation is for future policy to reflect the results of this study as 
substantiation that the development of a delivery system for the use of medicinal 
cannabis for U.S. patients merits consideration. This would allow patients who rely on 
cannabis for the treatment of disease to access to legally obtain, possess, and transport 
cannabis and to conduct activities related to individual needs.  
Interpretation of Results 
A review of various peer-reviewed articles and secondary data supported the 
importance of addressing the need for an increased understanding concerning the lack of 
and possibilities for the development of a delivery system to use medicinal cannabis for 
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the treatment of disease in the United States. Addressing this need came by comparing 
three core tenets of NORML’s patient-centric, evidence-based medical cannabis program 
to three exemplary state medical cannabis programs currently implemented. As supported 
in Chapter 2, when comparing NORML’s three core tenets to California, Colorado, and 
Nevada policies, it is clear that patient access to the whole cannabis plant is limited and 
varies from state to state.  
Interpretation supports policy feedback theory. The power of groups impacts 
political agendas, systems of governance, and future policies (Sabatier & Weible, 2014). 
Grounding this study is the idea that policies greatly shape an individual’s preferences 
and decisions. Policy feedback theory supported the customary principles of policies that 
impact those who rely on medicinal cannabis for the treatment of disease and who are in 
need a sound delivery system in the United States (Mettler & SoRelle, 2014).  
California’s policy does not specify means or amount of possession for patients; 
rather, access must be “consistent with the patient’s needs, that has been deemed 
appropriate and has been recommended by a physician” (Guidelines - Medical Marijuana, 
2016, n.p.). According to state policy, Colorado requires a “Medical Marijuana Registry 
Identification Card, and the patient may possess no more than 2 ounces of a usable form 
of marijuana” (State of Colorado, 2018, n.p.). Nevada’s policy asserts that patients may 
have access to 2.5 ounces and/or a determined allowable quantity of edible cannabis 
and/or marijuana-infused product within one 14-day period. Nevada also requires 




As found in this study, each of the three exemplary states met only some of 
NORML’s criteria for an expansive list of qualifying medical conditions. For instance, 
California’s policy offers a wide latitude for doctors to decide treatment regimens, 
provides a range of qualifying conditions, and also gives physicians allowance for any 
debilitating illness where medicinal cannabis is been “deemed appropriate and has been 
recommended by a physician” (California Department of Public Health, 2018, n.p.). 
Colorado’s policy also provides doctors wide latitude to decide treatment regimens, 
although qualifying conditions are more limited than with California’s policy (State of 
Colorado, 2018). While Nevada presents wide latitude for doctors to decide treatment 
regimens for qualifying conditions, the state provides limited conditions. 
Moreover, state laws restrict allowing patients the legal option to cultivate 
cannabis for personal use in their private residence, with regulations varying per state 
medical cannabis regulatory entities such as the Department of Health. For example, 
California limits a patient’s rights to cultivate as: 
[N]o more than six mature or twelve immature plants. Furthermore, Qualified 
Patients are exempt from state licensing requirements under MMRSA, if they 
cultivate 100 square feet or less of medical cannabis. Primary Caregivers serving 
up to five Qualified Patients may cultivate up to 500 square feet of medical 
cannabis without a state license. Cities and counties retain the right to license, 
regulate or ban medical cannabis cultivation. (California Department of Public 
Health, 2018, n.p.)  
Colorado’s policy is similar, albeit more limited:  
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[P]atients (or their primary caregivers) may cultivate no more than six marijuana 
plants, with three or fewer being mature, flowering plants that are producing a 
usable form of marijuana. Not more than six (6) marijuana plants, with three (3) 
or fewer being mature, flowering plants that are producing a usable form of 
marijuana. (State of Colorado, 2018, n.p.)  
Nevada’s policy is similar to California’s, but with another limitation:  
[The cultivation of] twelve marijuana plants, irrespective of whether the 
marijuana plants are mature or immature. Limits on home cultivation if patients 
reside within 25-miles of an operating dispensary. However, patients who are 
cultivating specific strains of cannabis not provided by a local dispensary may 
continue to engage in the home cultivation of such strains. (Nevada Division of 
Public and Behavioral Health, 2018, n.p.) 
The results of this study extend knowledge as anticipated in Chapter 2. NORML’s 
three core tenets provide a more broad-based model that includes a willingness to discard 
traditional policy for patients to have equal access and use medicinal cannabis for the 
treatment of disease in the United States. 
Limitations 
This cross-case analysis was critical for U.S. patients, physicians, state laws and 
policies, future researchers, and federal regulations. This study was important because of 
increasing attention to the benefits of cannabis for medical purposes and the lack of 
understanding regarding the need to develop of a delivery system for patients in the 
United States. The US lacks an existing formal delivery system for medicinal cannabis, 
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necessitating continued research at the state level to identify initiatives and systems 
possibilities. This study provided pertinent information regarding the lack of alignment of 
policies and laws across different states.  
I have identified two limitations to this study: sample size and demographics. This 
small sample population consisting of three exemplary states is not generalizable to a 
broader population, given that 30 additional state medical cannabis programs did not 
undergo comparison. The second limitation is due to the particular segment of the 
population and organization. The use of NORML’s three core tenets narrows the model 
for studying current and future regulatory efforts and policies impacting equal access for 
medicinal cannabis in the United States. 
Recommendations 
Recommendations for future research and policy change are considerable, 
grounded in the strengths and limitations of the existing body of literature as illustrated in 
Chapter 2. The use of medical cannabis has gained much ground and merits immediate 
consideration as a relevant option for those suffering with a medical illness. Both in the 
past and today, medical cannabis has been the answer for patients dealing with disease in 
the United States. Prior to the late 1930s, physicians could legally provide their patients 
with a prescription for cannabis.  
I make several recommendations for future research. The FDA (2019) does not 
approve indications for medicinal cannabis; rather, its focus is to evaluate research 
conducted by drug manufacturers and review data submitted to the FDA to ensure a drug 
product meets the statutory standards for approval. However, the FDA does not evaluate 
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or research the cannabis plant for medicinal value (FDA, 2019). The first 
recommendation is for the FDA to research, study, and evaluate medicinal cannabis and 
provide its findings to the DEA. 
Once the FDA has researched and evaluated the scientific effectiveness of 
cannabis as a medication with an accepted treatment through the FDA approval process, 
it can recommend the treatment to the DEA for review. The DEA then has the authority 
to reclassify medicinal cannabis into a less-restrictive category that would make it more 
readily available to physicians and patients. The next recommendation is for the revision 
of the Interstate Commerce Clause to exclude medical cannabis from the legislation. To 
make this happen, the change would require Congressional approval, a formal legislative 
action described by Article I, Section 10, Clause 3 of the Constitution. With 
Congressional consent, the Interstate Commerce Clause would transform federal law and 
allow for less restrictive businesses practices for medical cannabis dispensaries resulting 
in greater patient availability. The next recommendation for future study of medicinal 
cannabis is the reclassification of cannabis as a Schedule 2 or lower. The goal is to 
implement public policy by reclassifying the use of cannabis for medical purposes. This 
reclassification will help to improve the quality of life for people suffering from disease 
within the United States. This recommendation will enable patients and their medical 
team to devise the necessary treatment plans and medication decisions without the fear of 
government intervention or criminal prosecution.  
The final recommendation for future research is declassification. This would 
remove cannabis from the CSA entirely and allow patients and doctors to explore 
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medicinal cannabis and its use for the treatment of any disease deemed appropriate by 
both patient and doctor. In conjunction with policy feedback theory, people depend on 
empirical thought processes and rely on the social paradigm of complex policy 
development. The framework served as a model for this study, as it supported the need to 
improve understanding of the policy process. The ultimate goal is to educate doctors, 
citizens, politicians, and government officials regarding the positive therapeutic affect 
cannabis can have on individual patients and society as a whole. The integration of 
cannabis into the U.S. medical community will better serve patients with this form of 
treatment as an option. These recommendations do not exceed the study boundaries, as 
described previously.  
Implications 
This study’s contribution includes identification of how perceptions of regulatory 
efforts concerning medical cannabis shape policies that impact U.S. patients. This 
research is significant because of recognized gaps the perceptions of governing 
regulatory delivery systems and the existing body of literature focusing on the value of 
medicinal cannabis. To lead positive social change, the potential to improve the lives of 
patients in the United States may more readily occur through improved access of 
medicinal cannabis.  
The empirical implications are noteworthy, as acknowledging an alternate 
solution for a systematic delivery system for medicinal cannabis through change needed 
to future public policy is a significant step toward constructive social change. Policy 
feedback theory served to support this study, as the framework centers on the formation 
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of policy, examination of dynamics, and societal response to these policies (Mettler & 
SoRelle, 2014). Methodical implications from this study include incorporation of 
evidence-based research to support policy change for medical cannabis for the treatment 
of disease. By eliminating current restrictions on medical cannabis, greater liberty is 
available for physicians to authorize cannabis for the treatment of disease without the 
federal government prohibiting patient access in those states that have legalized 
medicinal cannabis.  
Amending federal law would decriminalize the cultivation, possession, and 
distribution of state-regulated medical cannabis. This will result in the FFDCA no longer 
superseding state law for permitting therapeutic use of medical cannabis. In addition, this 
will address the legislative bill known as the States Medical Marijuana Patient Protection 
Act, which reads in part: 
[N]o provision of the Federal Food, Drug, and Cosmetic Act shall prohibit or 
otherwise restrict an entity authorized by a state or local government, in a state in 
which the possession and use of marijuana for medical purposes is legal from 
producing, processing, or distributing marijuana for such purpose. (H.R. 689, 
2013, n.p.) 
The implications for social change do not exceed the study boundaries. As a result, the 
implications of this study are significant because they offer additional data that supports 





This study was vital to patients in the United States suffering from disease who 
will benefit from improved laws and policies governing cultivation, possession, and 
distribution of medicinal cannabis. This change is needed, as physicians are limited in or 
prohibited from authorizing the use of therapeutic cannabis. This study’s problem 
statement is that the United States does not have a formal delivery system for accessing 
medicinal cannabis, as federal law does not recognize the medicinal properties of 
cannabis. Policy feedback theory fully supports the social paradigm of policy design and 
was therefore the nature of this study. People as groups innately interpret the concept of 
policy as positive or negative based on heuristic thinking. Furthermore, the results 
indicated an overarching consensus concerning a lack of attention to consistent policies 
among three exemplary participant states and NORML, the leading cannabis authority 
used as the benchmark, which substantiate the importance of this study. The findings of 
this research support the need for attention to the possibilities for the development of an 
improved delivery system to treat U.S. patients. With an increase in the number of states 
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